although
major
children
asthma
achiev
symptom
control
low
moder
dose
mainten
inhal
steroid
small
proport
remain
uncontrol
despit
high
dose
prescrib
mainten
therapi
children
prescrib
treatment
equival
stage
british
thorac
societi
bt
guidelin
asthma
manag
either
need
least
amount
therapi
achiev
control
persist
symptom
frequent
exacerb
despit
maxim
treatment
children
poor
control
despit
maxim
prescrib
therapi
problemat
sever
asthma
howev
reason
poor
control
may
vari
broadli
divid
two
subcategori
first
difficult
asthma
term
use
describ
patient
whose
asthma
difficult
control
failur
address
basic
asthma
manag
incorrect
diagnosi
made
failur
address
associ
comorbid
underli
revers
modifi
factor
result
poor
control
includ
poor
adher
unfavour
environment
exposur
tobacco
smoke
aeroallergen
patient
sensitis
poor
inhal
techniqu
psychosoci
issu
modifi
factor
success
identifi
address
control
achiev
children
difficult
asthma
without
need
escal
therapi
addit
invas
investig
multidisciplinari
team
mdt
critic
enabl
modifi
factor
identifi
address
children
difficult
asthma
team
must
includ
specialist
respiratori
nurs
psychologist
pharmacist
physiotherapist
medic
staff
signific
resourc
therefor
requir
manag
paediatr
difficult
asthma
optim
specialist
centr
task
assess
patient
although
may
impact
healthcar
resourc
long
term
benefit
lung
health
signific
second
subcategori
children
poor
asthma
control
despit
maxim
therapi
true
sever
asthma
patient
remain
persist
symptom
control
maxim
dose
mainten
therapi
often
includ
oral
steroid
underli
revers
modifi
factor
identifi
address
importantli
half
children
problemat
sever
asthma
difficult
asthma
underli
modifi
revers
factor
prevent
asthma
control
therefor
overal
approach
manag
child
problemat
sever
asthma
includ
initi
step
identifi
treat
difficult
asthma
symptom
persist
true
sever
asthma
confirm
requir
addit
investig
manag
clear
criteria
definit
allow
distinct
difficult
sever
asthma
specifi
adult
children
age
six
year
european
respiratori
societi
american
thorac
societi
import
point
consid
face
child
poor
asthma
control
despit
maxim
dose
prescrib
mainten
therapi
threshold
treatment
equival
budesonid
child
refer
specialist
manag
nation
review
asthma
death
uk
identifi
asthma
death
occur
patient
refer
specialist
manag
problemat
asthma
modifi
factor
result
child
difficult
asthma
may
identifi
extrem
effici
mdt
approach
describ
adopt
howev
remain
equal
import
continu
assess
followup
patient
difficult
asthma
order
ensur
mainten
therapi
reduc
minim
amount
need
achiev
control
symptom
improv
modifi
factor
address
progress
true
sever
asthma
either
short
term
followup
longer
term
basic
inhal
techniqu
devic
adher
allergen
exposur
maintain
retrospect
analysi
followup
children
difficult
asthma
six
year
reveal
underli
modifi
factor
identifi
address
improv
lung
function
reduct
exacerb
time
abl
reduc
mainten
dose
inhal
steroid
major
fell
threshold
problemat
sever
asthma
howev
larg
drop
number
patient
could
trace
full
six
year
highlight
need
better
prospect
longitudin
data
outcom
children
difficult
asthma
miss
data
essenti
light
recent
cohort
studi
follow
children
sever
asthma
adulthood
shown
irrevers
reduct
lung
function
preval
copd
asthma
one
common
chronic
diseas
children
high
preval
mani
develop
develop
countri
worldwid
preval
asthma
children
vari
accord
intern
studi
asthma
allergi
childhood
issac
studi
despit
high
preval
inform
preval
sever
asthma
children
unknown
particularli
countri
transit
estim
come
differ
studi
shown
preval
sever
asthma
gener
popul
approxim
among
children
asthma
howev
true
preval
lowincom
countri
unknown
accord
issac
phase
iii
center
highest
preval
sever
asthma
symptom
mostli
english
languag
countri
latin
america
africa
indian
subcontin
eastern
mediterranean
lack
control
diseas
attribut
variou
factor
low
access
basic
medic
weak
healthcar
servic
poor
complianc
prescrib
therapi
lack
asthma
educ
social
cultur
factor
gener
asthma
children
adult
repres
signific
problem
public
health
given
reduc
qualiti
life
school
work
absente
increas
healthcar
cost
especi
countri
transit
addit
asthma
sever
control
childhood
particular
import
shown
translat
asthma
morbid
adulthood
practic
guidelin
address
manag
sever
asthma
children
point
variou
aspect
import
develop
condit
medic
issu
environ
asthma
educ
comorbid
psycholog
problem
worldwid
particularli
countri
transit
intrins
race
ethnic
weight
extrins
exposur
allergen
indoor
outdoor
pollut
factor
may
overlap
singl
child
enhanc
diminish
asthma
control
sever
differ
mani
develop
countri
contin
asthma
highli
preval
latin
america
moreov
issac
phase
iii
show
asthma
preval
region
still
rise
furthermor
evid
suggest
poorli
control
asthma
area
latin
america
lead
signific
econom
cost
attribut
emerg
unschedul
visit
high
mortal
rate
asthma
similar
region
asthma
control
obtain
patient
despit
avail
manag
guidelin
evid
ic
control
sever
survey
shown
close
patient
met
gina
criteria
total
asthma
control
propos
underrecognit
uncontrol
asthma
underus
appropri
control
treatment
inadequ
patient
educ
patient
denial
possibl
explan
also
sever
risk
factor
poverti
environment
factor
diet
genet
vitamin
defici
tobacco
smoke
detriment
effect
asthma
control
crosssect
data
children
asthma
costa
rica
suggest
low
serum
vitamin
detect
children
mild
moder
asthma
associ
asthma
sever
sinc
develop
worldwid
guidelin
diagnosi
manag
asthma
special
attent
achiev
maintain
asthma
control
key
goal
asthma
treatment
prioriti
clinic
studi
children
asthma
satisfactori
asthma
control
achiev
maintain
patient
regular
treatment
ic
nevertheless
larg
populationbas
survey
consist
show
poor
asthma
control
common
mani
children
asthma
despit
ic
treatment
sever
studi
shown
reduct
number
hospit
caus
asthma
variou
countri
transit
effect
prevent
control
measur
implement
mainli
avoid
risk
factor
import
use
basic
medic
patient
educ
patient
educ
caus
asthma
trigger
condit
monitor
manag
importantli
outcom
expect
recogn
lack
asthma
control
moreov
health
profession
also
educ
regard
underrecognit
undertreat
asthma
patient
parent
tend
deni
sever
symptom
recent
studi
perform
costa
rica
aim
examin
trend
hospit
mortal
due
asthma
period
particular
follow
nation
asthma
plan
nap
nap
consist
educ
meet
major
public
health
care
center
emphas
earli
diagnosi
earli
treatment
use
ic
firstlin
therapi
asthma
control
earli
use
reliev
medic
treat
exacerb
appropri
referr
specialist
asthma
care
avoid
common
allergen
sourc
eg
dustmit
cockroach
tobacco
smoke
concurr
program
gener
practition
pediatrician
internist
first
allow
prescrib
ic
asthma
pulmonologist
allergist
could
prescrib
ic
result
implement
nap
total
number
asthma
hospit
costa
rica
children
adult
decreas
approxim
period
children
younger
year
hospit
asthma
reduc
boy
girl
addit
number
death
due
asthma
decreas
period
mark
reduct
occur
implement
nap
parallel
decrement
asthma
hospit
mortal
number
prescript
ic
beclomethason
increas
summari
asthma
preval
depriv
region
high
show
increas
sever
reason
inadequ
asthma
control
poor
popul
includ
low
access
effect
control
medic
weak
infrastructur
health
servic
manag
chronic
diseas
poor
adher
therapi
lack
educ
approach
social
cultur
languag
barrier
howev
recent
studi
shown
sever
altern
control
burden
improv
outcom
urgent
need
research
sever
asthma
particular
children
countri
transit
becom
much
use
adag
asthma
singl
diseas
rather
multipl
diseas
present
common
symptom
paradigm
fundament
shape
way
think
asthma
possibl
approach
treatment
manag
strategi
one
treat
singl
diseas
talk
commonli
known
syndrom
asthma
need
personalis
medic
strategi
treat
differ
syndrom
alongsid
acknowledg
move
medicin
toward
personalis
treatment
manag
strategi
statist
machin
learn
instrument
help
us
shape
face
medicin
foster
engag
clinician
basic
scientist
statistician
mathemat
model
order
attain
unbias
approach
classifi
differ
subgroup
patient
use
probabilist
model
prolifer
genet
molecular
clinic
biolog
data
made
necessari
use
crossdisciplinari
approach
understand
underli
mechan
precipit
distinct
profil
asthma
allerg
diseas
childhood
statist
analysi
understand
subtyp
childhood
wheez
semin
paper
martinez
et
al
first
propos
exist
differ
subgroup
childhood
wheez
base
visual
assess
pattern
wheez
childhood
use
data
tuscan
children
respiratori
studi
identifi
four
group
wheezer
wheez
transient
earli
wheez
lateonset
wheez
persist
wheez
classif
use
classic
basi
subsequ
definit
distinct
subgroup
wheez
provid
build
block
statist
pattern
recognitionbas
method
identifi
heterogen
group
children
base
probabilist
model
longitudin
profil
asthma
wheez
time
one
statist
techniqu
latent
class
analysi
latent
class
analysi
assum
longitudin
fluctuat
observ
data
measur
uncertainti
uncertainti
due
random
error
anoth
element
uncertainti
may
due
exist
subgroup
latent
class
explain
heterogen
clinic
measur
directli
observ
henderson
et
al
first
appli
model
use
datadriven
approach
base
wheez
observ
avon
longitudin
studi
parent
children
use
latent
class
analysi
base
parent
report
wheez
group
identifi
two
addit
phenotyp
identifi
martinez
et
al
prolong
earli
intermediateonset
wheez
classif
replic
studi
one
caveat
base
model
strategi
parent
report
wheez
parent
may
abl
correctli
ascertain
clinic
diagnosi
wheez
light
belgrav
et
al
extend
method
jointli
model
data
parent
questionnair
gener
practition
record
provid
complementari
data
give
accur
measur
wheez
model
identifi
two
class
persist
wheez
persist
control
wheez
group
persist
troublesom
wheez
group
poorer
lung
function
reactiv
airway
compar
wheez
group
includ
persist
control
wheez
group
machin
learn
begin
statist
model
end
identifi
consist
defin
optim
number
subgroup
wheez
across
differ
cohort
challeng
within
era
big
data
rather
focus
tradit
statist
methodolog
medic
field
look
toward
data
scienc
mean
extract
knowledg
mean
vast
quantiti
inform
provid
clinic
data
achiev
tradit
statist
infer
method
base
robust
assumpt
machin
learn
model
amen
data
complex
breadth
depth
although
overlap
function
machin
learn
statist
flexibl
machin
learn
driven
toward
learn
data
integr
new
inform
order
updat
model
creat
accur
model
better
model
perform
programmat
focu
machin
learn
incorpor
vast
amount
comput
power
provid
excel
framework
tool
tradit
use
statist
model
would
unabl
accommod
larg
multiscal
dataset
near
futur
capabl
machin
learn
abl
learn
data
interact
may
facilit
computerassist
reason
identifi
subgroup
patient
identifi
subgroup
may
crucial
propos
effect
personalis
treatment
strategi
approach
also
allow
us
capitalis
exist
data
datatranspar
datashar
becom
widespread
global
commun
better
understand
evolut
asthma
allerg
diseas
research
identifi
heterogen
subgroup
asthma
allerg
diseas
reach
crucial
mileston
move
subject
approach
classifi
subgroup
wheezer
wherebi
clinician
give
clinic
assess
diagnosi
like
subgroup
base
observ
clinic
histori
move
toward
computerassist
reason
wherebi
use
new
inform
predict
like
class
assign
base
model
deriv
prospect
data
reason
would
also
allow
us
model
evolut
asthma
allerg
diseas
futur
popul
microb
bacteria
yeast
inhabit
skin
mucos
surfac
healthi
individu
host
thousand
differ
type
bacteria
differ
bodi
site
distinct
commun
estim
suggest
cell
human
bodi
microb
highest
densiti
greatest
divers
bacteria
found
within
gastrointestin
tract
research
suggest
relationship
microbiom
human
commens
nonharm
coexist
mutualist
symbiot
relationship
benefit
even
though
live
dirti
bacteri
world
infect
due
bacteria
rel
rare
individu
compet
immun
system
microorgan
make
microbiom
perform
wide
rang
use
function
ferment
unus
energi
substrat
educ
immun
system
prevent
growth
pathogen
regul
develop
organ
gut
produc
vitamin
host
produc
hormon
influenc
host
metabol
direct
host
store
fat
particular
specif
microbehost
interact
thought
critic
induc
mucos
toler
immun
regulatori
cell
treg
develop
toler
microb
live
us
us
perhap
consid
toler
altern
defens
strategi
continu
effort
involv
destroy
microb
surround
us
would
impair
organ
function
requir
vast
amount
energi
compat
life
reason
make
much
sens
robust
toler
mechan
work
tune
potent
effector
respons
ensur
optim
host
fit
intrigu
question
pose
concept
hygien
hypothesi
alter
exposur
microb
may
influenc
induct
tolerogen
immun
respons
therebi
make
individu
suscept
react
aggress
nondanger
encount
antigen
allergen
balanc
immun
toler
inflamm
regul
crosstalk
epitheli
immun
cell
microbiom
involv
mani
signal
pathway
molecul
direct
contact
bacterialassoci
structur
activ
receptor
eg
tlr
host
cell
induc
signal
cascad
result
innat
adapt
polar
immun
respons
microbiom
also
metabol
activ
microbi
metabolit
shown
exert
signific
effect
host
immun
signal
network
eg
scfa
biogen
amin
biogen
amin
histamin
promot
either
proor
antiinflammatori
effect
depend
four
receptor
activ
commens
bacteria
express
histidin
decarboxylas
enzym
need
convert
histidin
histamin
lactobacillu
saerimneri
produc
high
level
biolog
activ
histamin
feed
strain
mice
result
deterior
health
particularli
histamin
receptor
knockout
mice
signific
effort
underway
determin
posit
neg
health
effect
associ
product
histamin
microbiota
abnorm
microbiom
composit
andor
metabol
activ
shown
wide
rang
diseas
state
includ
diabet
obes
inflammatori
bowel
diseas
colorect
cancer
allergi
effort
use
microbiomeassoci
therapeut
eg
probiot
clearli
shown
benefici
effect
anim
model
inconsist
find
human
probabl
due
differ
bacteri
strain
use
one
probiot
bacterium
shown
consist
immunoregulatori
effect
murin
model
human
b
longum
subsp
longum
murin
model
demonstr
oral
consumpt
strain
result
induct
treg
cell
treg
cell
dampen
nfkb
activ
prevent
excess
inflamm
induc
salmonella
infect
similarli
human
oral
consumpt
induc
treg
cell
associ
increas
secret
peripher
blood
cell
interestingli
strain
reduc
system
proinflammatori
biomark
patient
psoriasi
ib
patient
chronic
fatigu
syndrom
patient
ulcer
coliti
mechan
involv
includ
recognit
bacterium
via
dcsign
myeloid
dendrit
cell
plasmacytoid
dendrit
cell
result
chang
dendrit
cell
cytokin
secret
product
metabolit
retino
acid
howev
effect
mechan
seen
even
close
relat
bacteri
strain
suggest
care
select
microb
essenti
futur
clinic
develop
immunotherapeut
microb
allergi
asthma
overal
conclud
vast
major
microb
interact
continu
host
bad
certain
specif
microb
posit
influenc
host
minor
neg
effect
host
gwa
find
base
upon
associ
pvalu
socal
genomewid
signific
well
replic
independ
popul
gener
requir
larg
sampl
size
order
obtain
team
scienc
approach
use
sever
studi
combin
data
metagwa
largest
gwa
asthma
date
combin
data
differ
studi
involv
individu
gabriel
consortium
identifi
genomewid
signific
asthma
loci
similar
metagwa
conduct
exampl
eagl
consortium
reveal
number
suscept
loci
asthmarel
trait
includ
feno
eczema
allerg
sensit
could
expect
larg
heterogen
diseas
phenotyp
introduc
combin
mani
differ
studi
metagwa
would
preclud
valid
discoveri
nevertheless
gwa
asthma
relat
trait
result
identif
rel
robust
loci
consist
studi
compar
previou
candid
gene
studi
one
exampl
first
largescal
gwa
allerg
sensit
metaanalysi
data
differ
studi
includ
discoveri
phase
approxim
case
control
similars
replic
phase
allerg
sensit
assess
object
defin
elev
level
allergenspecif
ige
andor
posit
skin
prick
test
studi
identifi
loci
associ
allerg
sensit
genomewid
signific
level
robust
replic
simultan
anoth
larg
gwa
perform
allerg
symptom
includ
approxim
individu
spite
larg
phenotyp
differ
two
studi
high
agreement
result
genomewid
signific
loci
sensit
studi
also
show
strong
associ
studi
allerg
symptom
previou
gwa
find
confirm
disappoint
result
gwa
identifi
loci
explain
minor
part
herit
suscept
variant
identifi
gwa
mainli
common
variant
rel
small
effect
size
often
odd
ratio
around
per
risk
allel
clinic
relev
individu
level
hand
gwa
identifi
novel
robust
suscept
loci
potenti
provid
import
understand
diseas
mechan
also
comparison
result
gwa
differ
diseas
trait
increas
understand
mechanist
relationship
exampl
relationship
allerg
sensit
asthma
allergenspecif
ige
total
ige
level
atopi
autoimmun
larger
consortiumbas
studi
asthma
relat
phenotyp
ongo
expect
identifi
mani
novel
suscept
loci
novel
loci
discov
larger
studi
like
even
smaller
effect
size
one
previous
found
perspect
understand
diseas
patholog
novel
locu
may
potenti
pinpoint
novel
mechan
potenti
treatment
target
furthermor
era
genomewid
nucleotid
sequenc
appli
gene
expressionand
epigenomeprofil
brought
new
possibl
combin
gwa
data
data
larg
public
omic
repositori
data
increas
use
gwa
data
provid
understand
function
effect
relat
suscept
loci
futur
gwa
asthma
relat
diseas
part
integr
approach
discov
differ
molecular
layer
modul
genet
effect
diseas
therebi
central
compon
attempt
tailor
improv
medic
treatment
asthma
highli
heterogen
diseas
probabl
consist
sever
subtyp
diseas
associ
differ
function
mechan
genet
loci
may
involv
specif
diseas
mechan
therebi
help
understand
heterogen
exampl
strongest
asthma
locu
identifi
gwa
locu
seem
strongli
associ
asthma
phenotyp
character
onset
earli
childhood
recurr
sever
exacerb
stronger
associ
asthma
allerg
rhiniti
contrast
anoth
locu
chromosom
associ
multipl
allergyrel
phenotyp
includ
allerg
sensit
allerg
symptom
eczema
asthma
suggest
differ
allergyrel
diseas
mechan
heterogen
natur
asthma
suggest
altern
increas
sampl
size
genet
studi
focu
specif
phenotyp
phenotyp
like
closer
associ
specif
mechan
genet
substrat
might
therefor
increas
studi
power
demonstr
gwa
focus
specif
asthma
phenotyp
character
onset
earli
childhood
recurr
sever
exacerb
spite
rel
small
sampl
size
studi
result
associ
result
magnitud
previou
much
larger
gwa
much
larger
effect
size
particularli
children
highest
number
exacerb
one
novel
asthma
gene
identifi
confirm
collabor
effort
involv
sever
birth
cohort
studi
locu
strongli
associ
asthma
exacerb
first
year
life
individu
european
noneuropean
ancestri
result
highlight
potenti
futur
genet
studi
focus
homogen
phenotyp
one
import
futur
step
translat
genet
associ
diseas
mechan
major
limit
gwa
often
mere
identifi
suscept
locu
without
clear
relationship
specif
gene
biolog
function
two
exampl
loci
mention
underli
mechan
still
poorli
understood
sever
year
discoveri
even
though
loci
strong
probabl
central
pathogenesi
asthma
allergi
one
exampl
gwa
discoveri
function
mechan
might
identifi
discoveri
studi
suggest
associ
asthma
caus
specif
function
variant
affect
surfac
express
later
studi
report
function
rhinoviru
c
receptor
show
function
variant
associ
asthma
exacerb
increas
rhinoviru
c
bind
replic
potenti
explain
underli
mechan
locu
identifi
target
futur
asthma
virolog
research
anoth
major
futur
challeng
understand
genet
suscept
interact
environment
factor
geneenviron
interact
account
normal
gwa
might
one
reason
larg
herit
explain
gwa
find
one
import
environment
risk
factor
childhood
asthma
wheez
disord
viral
infect
focus
environment
factor
might
tool
understand
mechan
asthma
gene
exampl
children
risk
variant
seem
suscept
rhinoviru
infect
find
seem
rhinoviru
c
receptor
indic
children
carri
risk
variant
specif
suscept
rhinoviru
c
infect
hypothesi
current
test
genomewid
geneenviron
interact
studi
perform
result
gener
disappoint
without
convinc
find
mani
inher
challeng
studi
first
might
requir
even
larger
sampl
size
normal
gwa
exact
inform
environment
exposur
difficult
obtain
largescal
studi
furthermor
effect
specif
environment
exposur
difficult
disentangl
relat
environment
factor
altern
approach
perform
cell
anim
model
specif
exposur
control
recent
studi
investig
potenti
protect
effect
endotoxin
farm
dust
exposur
mous
model
hous
dust
mitesensit
asthma
found
import
mediat
protect
effect
endotoxin
exposur
valid
human
bronchial
epitheli
cell
furthermor
potenti
modifi
effect
support
look
snp
locat
near
human
gene
use
data
earlier
genomewid
interact
studi
potenti
geneenviron
interact
need
replic
studi
exemplifi
mechanist
studi
target
specif
environment
exposur
use
experiment
model
facilit
identif
gene
involv
geneenviron
interact
conclus
improv
understand
genet
architectur
asthma
childhood
wheez
disord
requir
combin
gwa
focus
homogen
subtyp
diseas
geneenviron
interact
studi
birth
cohort
cell
model
integr
type
omic
data
challeng
overcom
team
scienc
approach
bring
togeth
mani
studi
provid
suffici
statist
power
bring
togeth
research
mani
disciplin
translat
clinic
associ
mechanist
understand
studi
present
great
challeng
also
opportun
understand
asthma
pathogenesi
heterogen
ultim
improv
prevent
treatment
diseas
recent
definit
chang
classifi
children
lower
chest
indraw
pneumonia
rather
sever
pneumonia
recommend
treatment
oral
antibiot
ambulatori
case
howev
recent
metaanalysi
report
singl
clinic
featur
suffici
accur
diagnos
radiolog
pneumonia
recommend
diagnost
sign
alon
lack
suffici
sensit
specif
particularli
identifi
children
need
antibiot
radiolog
diagnosi
pneumonia
reli
larg
chang
chest
xray
princip
consolid
interstiti
infiltr
howev
chest
xray
subject
variabl
interpret
expos
child
ioniz
radiat
requir
infrastructur
skill
recent
chest
ultrasound
suggest
feasibl
imag
modal
diagnosi
childhood
pneumonia
ultrasound
sever
advantag
includ
use
pointofcar
test
taught
nonradiologist
quick
perform
involv
exposur
radiat
initi
studi
suggest
high
sensit
specif
pneumonia
compar
chest
xray
diagnosi
etiolog
pneumonia
remain
challeng
bacteremia
rare
distinguish
colon
pathogen
organ
may
possibl
respiratori
specimen
coinfect
common
improv
specimen
collect
improv
molecular
techniqu
detect
organ
enabl
accur
detect
organ
howev
ascrib
etiolog
may
difficult
unless
organ
invari
pathogen
advanc
specimen
collect
includ
use
induc
sputum
infant
young
children
provid
better
specimen
detect
specif
pathogen
b
pertussi
tuberculosi
urin
antigen
detect
proven
use
pneumococc
pneumonia
pulmonari
tuberculosi
children
induc
sputum
test
sequenti
repeat
specimen
provid
higher
yield
pathogen
tuberculosi
care
attent
specimen
collect
method
use
differ
specimen
may
maxim
yield
especi
context
new
sensit
molecular
detect
techniqu
avail
improv
tool
etiolog
diagnosi
better
vaccin
coverag
conjug
vaccin
includ
pneumococc
conjug
vaccin
viral
pathogen
especi
rsv
bacteria
aureu
pertussi
emerg
promin
caus
childhood
pneumonia
area
high
tb
preval
tuberculosi
report
associ
acut
pneumonia
children
cultur
confirm
diseas
occur
approxim
case
howev
better
tool
detect
potenti
pathogen
also
provid
data
complex
etiolog
sever
potenti
pathogen
organ
frequent
identifi
singl
pneumonia
episod
delin
interact
differ
organ
pneumonia
pathogenesi
need
asthma
affect
mani
million
peopl
age
part
world
commonest
longterm
respiratori
condit
affect
children
develop
countri
preval
morbid
vari
ethnic
group
accur
diagnosi
effect
manag
respiratori
diseas
asthma
requir
object
measur
lung
function
reliabl
use
measur
possibl
appropri
norm
rang
avail
distinguish
effect
diseas
treatment
growth
develop
evid
ethnic
differ
lung
function
ethnic
differ
lung
function
well
document
past
attempt
interpret
observ
ethnic
differ
lung
function
often
confound
select
bia
relat
use
small
popul
sampl
necessarili
repres
generaliz
use
differ
method
equip
qualiti
control
qc
criteria
failur
adjust
import
determin
lung
function
includ
socioeconom
circumst
andor
inappropri
statist
analys
recent
year
mani
problem
address
appli
standard
methodolog
inclus
criteria
qc
larg
ethnic
homogen
group
current
research
show
adjust
age
sex
stand
height
forc
expir
volum
sec
fev
measur
airway
calibr
forc
vital
capac
fvc
measur
lung
size
reduc
approxim
individu
african
ancestri
black
across
entir
life
span
compar
european
ancestri
white
similar
though
smaller
reduct
observ
among
south
asian
indian
subcontin
southeast
asian
eg
china
thailand
malaysia
etc
subject
sinc
ethnic
reduct
fev
fvc
gener
proport
fev
fvc
ratio
commonli
use
outcom
assess
airway
obstruct
usual
independ
ethnic
background
suggest
structur
function
ethnic
differ
lung
design
thu
observ
ethnic
differ
lung
function
appear
primarili
limit
lung
size
rather
airway
dynam
respiratori
characterist
howev
adjust
factor
use
lung
volum
outcom
exampl
evid
lower
fvc
found
among
black
children
attribut
least
part
rel
high
residu
volum
suggest
factor
anatom
differ
diaphragmat
posit
respiratori
muscl
strength
might
contribut
observ
differ
furthermor
lung
function
indic
intern
adjust
size
individu
rest
lung
volum
lung
clearanc
index
lci
measur
ga
mix
effici
specif
airway
resist
sraw
measur
airway
calibr
adjust
lung
volum
appear
influenc
ethnic
background
nevertheless
sinc
larger
sampl
size
requir
confirm
find
data
interpret
lci
sraw
nonwhit
subject
current
undertaken
caution
recent
global
lung
function
initi
gli
collat
result
healthi
nonsmok
age
year
creat
first
allag
multiethn
refer
equat
spirometri
appropri
age
depend
lower
limit
normal
predict
equat
deriv
use
lm
method
allow
simultan
model
mean
mu
coeffici
variat
sigma
skew
lambda
distribut
refer
equat
deriv
caucasian
white
africanamerican
black
northand
southeast
asian
equat
enabl
assess
evalu
entir
age
rang
use
singl
refer
data
set
therebi
avoid
error
occur
switch
equat
particularli
transit
paediatr
adult
care
defin
ethnic
ethnic
extrem
difficult
defin
selfassign
ethnic
may
differ
observerassign
ethnic
certain
countri
law
record
ethnic
origin
purpos
furthermor
recent
census
uk
us
mixedrac
popul
shown
fastestgrow
ethnic
group
thu
classifi
ethnic
may
becom
increasingli
complex
task
could
differ
bodi
proport
explain
ethnic
differ
lung
function
stand
height
major
determin
lung
volum
reflect
fact
lung
size
adapt
metabol
need
howev
ideal
sinc
size
lung
close
relat
thorac
size
leg
length
differ
bodi
proport
may
underpin
much
observ
ethnic
variat
lung
function
size
lung
function
children
slic
studi
design
improv
norm
refer
rang
lung
function
take
differ
bodi
physiqu
account
facilit
earli
diagnosi
treatment
lung
diseas
children
irrespect
ethnic
background
howev
numer
addit
anthropometr
measur
undertaken
quantifi
bodi
physiqu
sit
height
chest
width
significantli
contribut
predict
spirometr
lung
function
chest
dimens
lean
mass
also
significantli
predict
fev
fvc
within
ethnic
group
affect
differ
group
persist
ethnic
differ
adjust
sit
height
chest
dimens
bodi
composit
socioeconom
factor
may
reflect
fact
factor
affect
chest
size
diaphragmat
posit
muscl
strength
assess
anthropometri
emphasis
import
take
ethnic
account
interpret
spirometri
data
studi
shown
associ
socioeconom
condit
sec
lung
function
suggest
key
factor
explain
ethnic
differ
lung
function
increas
evid
contribut
sec
variabl
lung
function
small
except
advers
condit
recent
studi
india
use
ident
equip
techniqu
use
slic
studi
found
averag
fev
fvc
urban
indian
children
similar
indian
children
resid
uk
significantli
higher
semiurban
rural
indian
children
respect
result
probabl
reflect
mark
differ
degre
social
depriv
uk
india
suggest
may
threshold
effect
poverti
lung
function
adjust
sit
height
shown
reduc
contribut
sec
ethnic
variabl
use
inappropri
refer
equat
misinterpret
lead
seriou
error
respect
underand
overdiagnosi
past
attempt
correct
ethnic
differ
made
tend
appli
fix
adjust
factor
across
age
ethnic
group
sex
spirometr
outcom
measur
approach
shown
oversimplist
addit
error
relat
ethnic
differ
lung
function
misdiagnosi
may
also
occur
fix
cutoff
predict
fev
fev
fvc
use
particularli
young
children
elderli
adult
predict
histor
use
interpret
lung
function
result
zscore
appropri
take
account
betweensubject
variabl
measur
given
outcom
given
age
well
predict
valu
similarli
use
fix
threshold
abnorm
fev
fvc
lead
gross
underdiagnosi
airway
obstruct
young
overestim
elderli
except
extrem
depriv
ethnic
differ
lung
function
explain
socioeconom
factor
adjust
confound
genet
factor
contribut
ethnic
differ
bodi
physiqu
lung
function
given
mark
ethnic
differ
lung
function
magnitud
similar
across
entir
life
span
essenti
lung
function
result
children
interpret
use
ethnic
specif
equat
whether
clinic
practic
epidemiolog
research
although
never
cover
ethnic
group
appropri
use
age
height
sex
adjust
valu
fev
fvc
ratio
deriv
equat
consist
across
ethnic
group
facilit
better
identif
airway
obstruct
children
irrespect
ethnic
background
failur
adjust
lung
function
ethnic
differ
result
overestim
sever
airway
obstruct
sever
preval
restrict
lung
diseas
recognis
asthma
complex
heterogen
diseas
therefor
need
move
away
offer
singl
approach
manag
children
consid
identif
individu
phenotyp
child
enabl
optim
treatment
control
specif
facet
diseas
need
consid
defin
child
includ
accur
descript
symptom
pattern
exacerb
alon
persist
symptom
without
exacerb
ii
natur
airway
inflamm
eosinophil
neutrophil
noninflam
iii
type
degre
structur
airway
chang
remodel
although
asthma
control
achiev
children
lowmoder
dose
inhal
steroid
remain
unclear
choic
optim
mainten
therapi
child
decis
regular
inhal
steroid
leukotrien
receptor
antagonist
made
addit
therapi
requir
achiev
control
scientif
rational
addon
therapi
also
unavail
major
decis
therapi
made
use
trial
treatment
approach
one
approach
success
anoth
adopt
without
clear
thought
process
dictat
choic
treatment
appar
need
chang
current
one
size
fit
approach
manag
asthma
children
although
perhap
less
import
children
mild
moder
diseas
becom
extrem
import
consid
sever
diseas
personalis
medicin
sever
asthma
although
atopi
airway
hyperrespons
eosinophil
inflamm
remodel
cardin
pathophysiolog
featur
paediatr
asthma
know
featur
present
differ
degre
individu
child
patholog
studi
children
sever
diseas
although
featur
eosinophil
inflamm
increas
airway
smooth
muscl
repres
patient
group
huge
overlap
children
without
asthma
huge
spread
sever
featur
within
group
children
sever
asthma
withingroup
variabl
mean
assess
need
made
individu
decid
appropri
addon
therapi
propos
approach
identifi
individu
phenotyp
children
sever
asthma
split
respons
steroid
differ
domain
bossley
c
et
al
j
allergi
clin
immunol
press
children
asthma
abnorm
lung
function
inflamm
remodel
respons
trial
system
steroid
therefor
split
follow
lung
function
respons
ii
inflamm
respons
exhal
nitric
oxid
sputum
eosinophil
iii
symptom
respons
analys
approach
patient
sever
therapi
resist
asthma
shown
similar
proport
children
approx
respond
system
corticosteroid
domain
reliabl
predictor
respons
pattern
furthermor
complet
respond
respons
domain
nonrespond
respons
domain
major
partial
respond
respons
domain
data
highlight
childhood
sever
asthma
heterogen
complet
respons
symptom
inflammatori
physiolog
paramet
rare
bossley
c
et
al
j
allergi
clin
immunol
press
individu
respons
pattern
system
steroid
need
appli
futur
guid
choic
addon
therapi
child
step
toward
achiev
personalis
medicin
subsequ
multidomain
approach
appli
clinic
identifi
characterist
respond
addon
therapi
omalizumab
becam
appar
posit
respons
inflamm
domain
signific
reduct
exhal
nitric
oxid
trail
system
steroid
benefici
respons
omalizumab
increas
number
addon
therapi
becom
avail
use
specif
context
sever
asthma
need
better
defin
pathophysiolog
phenotyp
individu
patient
need
understand
mechan
mediat
diseas
children
addit
need
incorpor
individu
genotyp
definit
phentoyp
accur
defin
treatment
respons
success
done
respons
montelukast
preschool
wheez
individualis
approach
allow
us
discov
novel
molecular
target
effect
specif
paediatr
popul
also
enabl
us
object
choos
best
therapi
tailor
individu
child
europ
consist
report
children
recogn
asthma
diagnosi
requir
acut
medic
care
yearli
reflect
inadequaci
avail
treatment
option
prevent
treatment
exacerb
suggest
asthma
sever
exacerb
may
repres
distinct
subtyp
diseas
demonstr
need
improv
understand
pathogenesi
asthma
herit
estim
number
gene
verifi
genomewid
associ
studi
gwa
still
genet
background
asthma
remain
poorli
understood
larger
gwa
may
reveal
new
suscept
loci
smaller
effect
due
larg
heterogen
asthma
altern
strategi
may
increas
phenotyp
specif
specif
phenotyp
like
closer
relat
specif
pathogenet
mechan
may
therefor
markedli
increas
power
genet
studi
background
gwa
focus
particular
asthma
phenotyp
defin
repeat
sever
exacerb
earli
childhood
suffici
number
case
obtain
identif
children
recurr
acut
hospit
asthma
year
age
danish
nation
patient
regist
extract
dna
dri
blood
spot
danish
newborn
screen
biobank
case
phenotyp
rare
children
born
denmark
fulfil
inclus
criteria
final
studi
compris
children
repeat
hospit
healthi
control
five
loci
identifi
genomewid
signific
associ
pvalu
gsdmb
even
though
sampl
size
gwa
less
one
fifth
largest
publish
gwa
asthma
gabriel
consortium
identifi
similar
number
genomewid
signific
loci
similar
statist
signific
effect
estim
remark
high
odd
ratio
per
risk
allel
compar
odd
ratio
around
usual
found
gwa
complex
trait
increas
phenotyp
specif
stratifi
analysi
children
highest
number
exacerb
result
increas
effect
estim
odd
ratio
per
risk
allel
strong
statist
signific
strong
result
demonstr
valu
focus
specif
phenotyp
asthma
genet
furthermor
indic
studi
sever
earlyonset
phenotyp
cost
effect
approach
wherebi
methodolog
requir
larg
resourc
andor
strong
statist
power
appli
limit
number
individu
still
provid
power
result
toplocu
studi
chromosom
near
gsdmb
consist
associ
childhood
onset
asthma
effect
size
present
studi
remark
pvalu
increas
children
highest
number
exacerb
suggest
import
role
locu
sever
exacerb
earli
childhood
line
previou
report
copsac
birth
cohort
studi
previous
associ
asthma
diseas
associ
asthma
replic
public
avail
gabriel
result
protein
structur
model
show
riskassoci
variant
locat
interfac
two
domain
could
involv
disulfid
rearrang
interfer
interdomain
stabil
overal
protein
stabil
conform
agreement
observ
experiment
studi
alter
cell
surfac
express
biolog
function
unknown
seem
highli
plausibl
asthma
gene
belong
cadherin
gene
famili
transmembran
protein
involv
sever
cellular
process
includ
epitheli
polar
cellcel
interact
differenti
highli
express
lung
also
member
cadherin
famili
associ
asthma
relat
trait
includ
ecadherin
recent
report
function
receptor
rhinoviru
c
differenti
express
epitheli
cell
suscept
rhinoviru
c
infect
compar
unsuscept
cell
express
epitheli
cell
enabl
rhinoviru
c
bind
replic
importantli
introduct
risk
variant
transfect
result
increas
rvc
bind
progeni
yield
compar
nonrisk
variant
data
provid
strong
evid
rhinoviru
c
receptor
associ
signal
gene
might
result
increas
suscept
rvc
infect
find
line
exacerbationrel
phenotyp
discoveri
gwa
sinc
rhinoviru
c
report
common
viral
trigger
sever
asthma
exacerb
children
associ
sever
diseas
higher
rate
hospit
readmiss
compar
respiratori
viral
infect
correct
would
indic
children
risk
variant
specif
suscept
rhinoviru
c
infect
compar
ill
trigger
virus
hypothesi
current
test
conclus
strong
result
found
gwa
childhood
asthma
sever
exacerb
demonstr
valu
specif
phenotyp
search
asthma
gene
focus
extrem
subtyp
diseas
might
reveal
mechan
would
reveal
studi
milder
diseas
might
also
increas
understand
gener
asthma
mechan
identif
risk
gene
might
one
first
exampl
underli
mechan
asthma
gwa
find
understood
futur
studi
gene
may
improv
understand
treatment
asthma
exacerb
childhood
time
bacteri
colon
earli
life
thought
import
appropri
immun
educ
transmiss
mother
fetu
pregnanc
birth
better
describ
cultur
meconium
shown
divers
group
gramposit
gramneg
bacteria
possibl
deriv
postdeliveri
develop
gut
microbiom
dynam
process
earli
colon
bacteroid
bifidobacterium
speci
might
play
crucial
role
develop
immun
regul
factor
influenc
earli
life
colon
includ
antibiot
treatment
method
deliveri
matern
infant
diet
biodivers
home
surround
environ
famili
member
gut
microbiom
increas
divers
first
year
life
germfre
mice
expos
live
bacteria
display
exagger
ige
respons
associ
diminish
polar
treg
cell
monocolon
mice
specif
microb
microb
suppress
ige
respons
promot
treg
differenti
howev
certain
immunolog
chang
increas
inkt
number
mucosa
revers
follow
colon
mice
later
life
interestingli
sever
allerg
respons
anaphylaxi
observ
mice
receiv
microbiom
transplant
allerg
anim
suggest
certain
microbi
speci
actual
promot
allerg
respons
immun
system
birth
domin
cell
howev
human
fetu
function
immun
system
rel
earli
statu
develop
compris
cell
also
treg
cell
one
concept
gain
support
develop
fetu
may
becom
educ
whole
bacteria
genet
materi
provid
via
matern
serum
dna
bifidobacteria
lactobacilli
two
genera
typic
use
probiot
found
human
placenta
contrast
utero
exposur
potenti
pathogen
bacteria
ureaplasma
speci
lead
immun
dysregul
commonli
end
fatal
complic
matern
consumpt
probioticcontain
food
compon
may
reduc
risk
childhood
allerg
diseas
mous
model
demonstr
reduc
risk
inflammatori
bowel
diseas
epigenet
mechan
may
critic
sinc
applic
acinetobact
lwoffii
pregnant
mice
reduc
airway
hypersensit
respons
offspr
promot
region
ifng
cell
offspr
high
level
acetyl
associ
enhanc
transcript
promot
region
lower
level
acetyl
moreov
exposur
pregnant
mother
farm
environ
high
level
acinetobact
lwoffii
associ
dna
demethyl
locu
methyl
gene
sinc
gut
microbiota
composit
first
month
life
seem
import
develop
appropri
immun
regulatori
network
therebi
influenc
later
life
diseas
risk
intervent
probiot
prebiot
synbiot
might
effect
age
even
pregnanc
probiot
defin
live
microorgan
administ
adequ
amount
confer
health
benefit
host
notabl
definit
probiot
differenti
wide
rang
potenti
health
benefit
clear
probiot
influenc
immun
system
way
find
observ
one
probiot
strain
extrapol
probiot
strain
current
evid
indic
probiot
clinic
test
date
reduc
risk
children
develop
allergi
signific
differ
studi
use
differ
probiot
strain
differ
age
group
differ
endpoint
despit
poor
qualiti
evid
suggest
may
benefit
specif
high
risk
group
pregnant
women
high
risk
allerg
child
women
breastfe
infant
high
risk
allergi
infant
high
risk
develop
allergi
gener
probioticsuppl
formula
found
well
toler
safe
infant
conclus
better
descript
bacteri
strain
metabolit
influenc
immun
function
requir
order
allow
improv
design
select
futur
probiot
strain
prevent
treatment
allerg
disord
peopl
cystic
fibrosi
cf
live
longer
live
ever
past
median
predict
surviv
develop
countri
year
age
adult
cf
outnumb
pediatr
patient
sever
region
variou
reason
may
explain
improv
life
expect
includ
establish
cfdedic
multidisciplinari
center
greater
attent
nutrit
issu
use
pancreat
enzym
replac
therapi
airway
clearanc
techniqu
tailor
individu
need
attitud
infect
control
measur
use
antibiot
chronic
inhal
aggress
treat
pulmonari
exacerb
mucolyt
airway
hydrat
therapi
liver
lung
transplant
account
overwhelm
evid
organ
impair
begin
earli
even
asymptomat
cf
infant
gener
consensu
least
strategi
care
implement
soon
possibl
order
prevent
delay
irrevers
structur
lung
damag
inde
possibl
main
argument
favor
cf
nb
strength
argument
test
sever
studi
consid
differ
approach
random
studi
two
random
trial
newborn
screen
cf
complet
evalu
need
mani
year
followup
given
high
degre
evid
favor
cf
newborn
screen
present
avail
implement
similar
studi
seem
improb
possibl
non
ethic
observ
studi
although
studi
confirm
clinic
benefit
earli
diagnosi
cf
result
hamper
sever
bias
inher
methodolog
approach
constant
improv
treatment
consequ
longer
surviv
influenc
comparison
screen
individu
unscreen
histor
control
hand
examin
clinic
evolut
screen
infant
unscreen
control
differ
geograph
area
born
year
may
affect
differ
care
practic
final
ascertain
bias
may
also
impact
assess
outcom
patient
present
clinic
like
sever
cf
identifi
screen
unscreen
patient
critic
diseas
may
die
diagnos
health
econom
studi
studi
use
surrog
endpoint
quantiti
treatment
need
remain
healthi
base
assumpt
optim
manag
offer
cf
patient
make
harder
detect
evid
better
clinic
outcom
diagnos
screen
latediagnos
patient
may
show
clinic
pictur
similar
diagnos
earli
expens
consider
heavier
burden
care
studi
focus
respiratori
nutrit
outcom
hta
assess
overal
result
clearli
point
direct
posit
effect
height
weight
longer
surviv
health
servic
save
popul
screen
birth
cf
posit
effect
may
also
obtain
sever
domain
name
prevent
salt
loss
syndrom
thank
earli
begin
salt
supplement
opportun
survey
birth
natur
histori
cf
better
understand
earli
stage
cf
possibl
test
presymptomat
therapeut
strategi
convent
patient
target
cystic
fibrosi
cf
associ
presenc
two
cfcaus
mutat
one
parent
cftr
gene
result
absenc
abnorm
cftr
protein
defect
electrolyt
transport
across
epitheli
membran
well
known
sweat
chlorid
mmoll
even
cf
remain
essenc
clinic
diagnosi
wide
rang
sever
symptom
organ
involv
within
individu
make
clinic
decis
whether
person
manag
cf
patient
especi
case
small
number
ambigu
atyp
case
first
diagnosi
consensu
list
criteria
cf
diagnosi
one
phenotyp
featur
diseas
ii
cf
sibl
iii
posit
immunoreact
trypsin
irt
associ
least
one
featur
includ
posit
sweat
test
result
two
occas
cfcaus
mutat
cftr
gene
abnorm
nasal
potenti
differ
npd
consensu
statement
us
cystic
fibrosi
foundat
later
modifi
europ
base
concept
cftr
dysfunct
includ
diagnosi
algorithm
atyp
cf
patient
diagnos
base
sweat
test
andor
genet
analysi
mild
cf
individu
usual
present
later
live
pancreat
suffici
milder
respiratori
diseas
frequent
carri
wide
clinic
spectrum
mutat
difficulti
occur
patient
present
clinic
symptom
suggest
cf
sweat
chlorid
valu
intermedi
rang
mmoll
among
subject
abnorm
npd
measur
identifi
cftr
mutat
averag
sever
lung
diseas
remain
subject
although
diseas
symptom
milder
subject
sweat
chlorid
concentr
mmoll
therefor
physician
also
patient
perspect
individu
must
differenti
subject
classic
lifeshorten
form
cf
remain
case
term
possibl
borderlin
difficult
classifi
poor
agreement
sweat
test
result
prognosi
one
hand
frequent
presenc
least
one
cftr
mutat
uncertain
clinic
relev
term
cftrrelat
disord
cftrrd
design
vari
condit
includ
multisystem
diseas
monosymptomat
disord
associ
cftr
dysfunct
fulfil
diagnost
criteria
cf
encompass
main
clinic
entiti
cftr
dysfunct
cbavd
congenit
bilater
absenc
va
deferen
acut
recurr
chronic
pancreat
dissemin
bronchiectasi
diagnosi
cbavd
base
impalp
va
deferen
scrotal
examin
even
proport
men
scrotal
palpabl
va
deferen
present
surgic
explor
reveal
fibrou
cord
nonperm
duct
cbavd
male
either
sever
mildvari
two
mild
variabl
cftr
mutat
approxim
men
cbavd
cftr
mutat
one
gene
splice
variant
allel
often
associ
longer
polymorph
dinucleotid
repeat
combin
result
cf
reduc
level
function
cftr
protein
wolffian
tissu
constitut
produc
less
fulllength
cftr
mrna
tissu
patient
idiopath
chronic
pancreat
recurr
acut
pancreat
found
carri
cftr
mutat
specif
cftr
mutat
report
rare
class
class
mutat
often
found
increas
incid
cftr
gene
mutat
found
bronchiectasi
accord
studi
least
cftr
mutat
found
mutat
case
mutat
found
mostli
uncommon
like
result
residu
cftr
function
specif
cftr
mutat
associ
directli
bronchiectasi
patient
must
monitor
care
develop
complic
appropri
therapi
implement
point
howev
label
patient
mild
unclear
manifest
cf
diagnosi
may
neg
implic
psycholog
reproduct
social
employ
insur
issu
therefor
explan
diagnost
challeng
includ
also
prognosi
must
fulli
honestli
explain
patient
famili
depart
pediatr
cf
pcd
center
hadassah
hebrewunivers
medic
center
mount
scopu
jerusalem
eitank
hadassahorgil
effect
mucociliari
clearanc
mcc
respiratori
system
requir
proper
mucu
product
function
airway
surfac
fluid
layer
well
compet
coordin
ciliari
beat
vital
role
system
best
demonstr
patient
genet
defect
primari
ciliari
dyskinesia
pcd
cystic
fibrosi
cf
character
impair
mcc
lead
acut
chronic
sinopulmonari
infect
pcd
caus
defect
gene
encod
structur
regul
movement
function
respiratori
cilia
cf
caus
mutat
cftr
gene
caus
abnorm
airway
surfac
fluid
layer
product
thicken
viscou
mucu
lead
impair
mcc
diseas
recurr
chronic
respiratori
infect
persist
inflamm
caus
progress
lung
damag
patient
cf
suffer
pancreat
insuffici
cfpi
howev
approxim
suffici
pancreat
enzym
product
maintain
normal
fat
absorpt
cfp
patient
pcd
similar
patient
cfp
normal
pancreat
function
usual
without
nutrit
defici
typic
associ
sever
pulmonari
diseas
cf
addit
pcd
cfp
often
diagnos
later
age
better
surviv
compar
cfpi
therefor
compar
cf
pcd
one
differenti
patient
cfpi
cfp
santamaria
et
al
compar
chest
hrct
scan
score
patient
pcd
group
ageand
gendermatch
cf
patient
show
patient
pcd
significantli
less
structur
damag
cf
patient
recent
studi
compar
pcd
cfp
cfpi
reveal
patient
pcd
diseas
sever
term
pulmonari
function
structur
abnorm
similar
patient
cfp
significantli
less
sever
compar
patient
cfpi
furthermor
compar
structur
abnorm
hrct
signific
dispar
distribut
structur
chang
lung
three
group
patient
pcd
upper
lung
zone
rel
preserv
chang
local
middl
lower
lobe
wherea
cfpi
upper
lobe
remark
involv
cfp
characterist
distribut
structur
damag
studi
show
pcd
contrari
cf
group
correl
fev
ct
score
fev
age
provid
support
understand
pcd
lung
function
strong
indic
sever
lung
diseas
therefor
followup
low
radiat
chest
hrct
scan
consid
import
note
gener
patient
pcd
receiv
less
intens
therapi
alway
follow
regularli
special
center
mani
adher
routin
treatment
common
bacteri
infect
pcd
patient
h
influenza
significantli
less
common
older
cf
patient
cf
chronic
infect
p
aeruginosa
associ
sever
lung
diseas
howev
among
patient
pcd
correl
p
aeruginosa
infect
pulmonari
function
hrct
sever
score
suggest
differ
role
microorgan
pathogenesi
pulmonari
diseas
pcd
bush
et
al
compar
mucou
properti
diseas
demonstr
inflamm
measur
concentr
greater
pcd
sputa
signific
differ
biophys
transport
properti
sputum
two
group
howev
surviv
patient
pcd
gener
better
ratjen
et
al
assess
inflammatori
respons
airway
cf
pcd
patient
pulmonari
exacerb
stabl
pcd
patient
signific
differ
found
sputum
inflammatori
marker
individu
colon
differ
bacteri
pathogen
howev
higher
bacteri
densiti
aureu
h
influenza
found
patient
cf
versu
pcd
absolut
neutrophil
count
higher
pcd
patient
sputum
elastas
activ
similar
pcd
cf
time
exacerb
decreas
antibiot
therapi
pcd
cf
patient
thu
pcd
patient
differ
cf
respons
treatment
pulmonari
exacerb
higher
neutrophil
elastas
activ
persist
cf
airway
end
treatment
joenesen
et
al
measur
differ
breath
profil
patient
pcd
cf
without
distinct
chronic
lung
infect
use
electron
nose
signific
differ
found
breath
profil
pcd
patient
chronic
pa
infect
pcd
patient
without
chronic
infect
howev
signific
differ
breath
profil
cf
patient
chronic
pa
infect
cf
patient
without
chronic
pa
infect
suggest
differ
respons
infect
pcd
cf
conclus
although
pcd
cf
character
impair
mcc
respiratori
infect
patient
pcd
differ
lung
diseas
express
compar
patient
cfp
cfpi
assess
fev
hrct
nutrit
statu
bacteri
infect
sputum
cultur
pcd
normal
fev
maintain
time
spite
sever
structur
damag
suggest
greater
involv
larg
airway
pcd
small
airway
cf
furthermor
p
aeruginosa
infect
less
common
pcd
cf
bronchopulmonari
dysplasia
bpd
import
complic
follow
mechan
ventil
preterm
infant
definit
therapi
elimin
complic
although
mechan
complet
clear
pulmonari
inflamm
believ
play
central
role
pathogenesi
glucocorticoid
one
effect
therapi
treat
prevent
bpd
howev
system
glucocorticoid
therapi
gener
recommend
longterm
advers
event
previou
pilot
studi
neonat
studi
anim
indic
surfact
use
vehicl
deliv
topic
glucocorticoid
budesonid
lung
peripheri
effect
suppress
lung
inflamm
lung
injuri
mechan
effect
deliveri
budesonid
use
surfact
vehicl
base
physic
phenomenon
marangoni
effect
interfac
high
low
surfac
tension
convect
forc
gener
forc
use
vehicl
facilit
deliveri
medic
import
deliveri
method
inhal
glucocorticoid
technic
difficult
effect
shown
limit
signific
differ
group
studi
serum
electrolyt
glucos
bun
blood
pressur
physic
growth
signific
differ
group
neuromotor
function
mdi
pdi
neurodevelopment
impair
ndi
score
examin
year
correct
age
conclud
low
birth
weight
infant
sever
respiratori
distress
syndrom
intratrach
administr
surfactantbudesonid
compar
surfact
alon
significantli
decreas
incid
bpd
death
without
appar
short
term
long
term
advers
effect
largesampl
doubleblind
trial
warrant
measur
lung
function
noncollabor
children
alway
one
difficult
task
pediatr
pulmonologist
young
children
abl
perform
voluntari
forc
expiratori
maneuv
gener
use
adult
schoolchildren
infant
children
year
problem
gener
overcom
use
sedat
although
contribut
make
lung
function
measur
less
suitabl
routin
clinic
use
age
group
preschool
children
year
old
sedat
yet
young
properli
perform
forc
expiratori
maneuv
requir
spirometri
age
group
sever
techniqu
requir
tidal
breath
implement
past
decad
american
thorac
societyeuropean
respiratori
societi
atser
work
group
lung
function
young
children
publish
technic
recommend
infant
preschool
techniqu
clinic
applic
also
recent
summar
lectur
focu
use
pulmonari
function
test
pft
infant
preschool
children
chloral
hydrat
mgkg
maximum
g
commonli
use
sedat
infant
young
children
year
perform
lung
function
test
howev
chloral
hydrat
longer
avail
usa
use
sed
might
lead
differ
result
commonli
use
pft
infant
rais
volum
rapid
thoracoabdomin
compress
infant
plethysmographi
pft
perform
tidal
breath
eg
tidal
breath
measur
multipl
breath
washout
forc
oscil
techniqu
suitabl
use
without
sedat
especi
younger
infant
rais
volum
rapid
thoracoabdomin
compress
rvrtc
allow
measur
forc
expiratori
flow
volum
sedat
infant
repeat
inflat
use
pressur
cmh
appli
facemask
inflat
jacket
activ
rapidli
compress
infant
chest
abdomen
obtain
forc
vital
capac
fvc
forc
expiratori
volum
second
fev
forc
expiratori
flow
fef
defin
proport
fvc
ensur
flow
limit
reach
inflat
pressur
jacket
increas
maneuv
increas
flow
notic
recent
publish
refer
equat
use
current
commerci
avail
devic
improv
interpret
result
rvrtc
success
use
children
kind
respiratori
diseas
includ
children
cystic
fibrosi
cf
children
born
prematur
recurr
wheez
show
capabl
distinguish
diseas
popul
healthi
control
subject
detect
lung
function
chang
clinic
intervent
trial
howev
longterm
clinic
util
still
remain
establish
moreov
need
sedat
along
time
resourc
intens
requir
import
limit
use
routin
clinic
practic
infant
plethysmographi
use
measur
function
residu
capac
frcpleth
sedat
infant
specif
airway
resist
sraw
also
measur
provid
proper
electron
thermal
compens
appli
system
account
thermal
artifact
techniqu
base
principl
boyl
law
plethysmographi
older
subject
use
infant
whole
bodi
plethysmograph
infant
lie
supin
breath
facemask
seal
silicon
putti
infant
plethysmographi
success
appli
children
lung
diseas
especi
cf
bronchopulmonari
dysplasia
bpd
howev
rvrtc
longterm
clinic
util
remain
ascertain
role
routin
clinic
practic
henc
limit
preschool
children
year
old
sedat
also
young
properli
perform
forc
expiratori
maneuv
requir
spirometri
age
group
sever
techniqu
requir
tidal
breath
implement
past
decad
allow
lung
function
measur
awak
children
also
modifi
accept
criteria
spirometri
propos
use
preschool
children
import
highlight
feasibl
lung
function
techniqu
preschool
children
strongli
depend
capabl
oper
keep
child
quiet
focus
spirometri
propos
preschool
children
use
modifi
accept
criteria
sinc
forc
expiratori
volum
second
fev
often
obtain
preschool
due
differ
lung
physiolog
use
fev
fev
second
fev
recommend
age
group
also
fvc
report
flow
stop
peak
flow
earli
termin
fev
may
still
report
less
stringent
repeat
criteria
also
propos
preschool
children
least
two
accept
maneuv
obtain
two
fvc
fev
within
ml
case
singl
accept
maneuv
record
nevertheless
spirometri
report
feasibl
year
old
children
feasibl
tend
much
lower
younger
children
global
multiethn
refer
equat
includ
preschool
children
recent
publish
spirometri
report
discrimin
healthi
control
preschool
children
cf
recurr
wheez
although
substanti
overlap
group
may
occur
bronchodil
respons
appear
sensit
baselin
valu
howev
care
rigor
approach
use
spirometri
must
taken
preschool
children
sever
gap
knowledg
still
limit
applic
techniqu
clinic
practic
age
group
interrupt
techniqu
base
principl
sudden
flow
interrupt
mouth
tidal
breath
would
make
alveolar
pressur
rapidli
equilibr
mouth
pressur
thu
allow
estim
alveolar
pressur
measur
mouth
pressur
interrupt
resist
r
int
calcul
divid
chang
mouth
pressur
flow
measur
immedi
interrupt
classic
techniqu
immedi
interrupt
open
techniqu
measur
r
int
prove
particularli
suitabl
preschool
children
feasibl
gener
higher
age
group
proper
refer
valu
publish
cutoff
valu
bronchodil
respons
also
report
r
int
abl
detect
chang
airway
calib
success
use
preschool
children
recurr
wheez
howev
util
clinic
care
remain
establish
especi
longitudin
studi
forc
oscil
techniqu
fot
use
measur
imped
respiratori
system
z
rs
tidal
breath
appli
mouthpiec
filter
lowfrequ
pressur
oscil
gener
loudspeak
usual
hz
chang
flow
pressur
measur
mouth
use
calcul
z
rs
two
compon
resist
r
rs
reflect
friction
loss
reactanc
x
rs
reflect
elast
properti
low
frequenc
inerti
forc
higher
frequenc
forc
signal
base
sinusoid
wave
impuls
use
singlefrequ
composit
signal
frequenc
hz
consid
reflect
mechan
properti
total
airway
fot
good
feasibl
preschool
children
sever
refer
equat
publish
fot
use
mani
studi
children
recurr
wheez
show
good
capabl
discrimin
health
diseas
especi
bronchodil
respons
use
howev
techniqu
well
longitudin
studi
clinic
util
young
children
still
need
multipl
breath
washout
mbw
base
washout
inert
ga
typic
n
washout
use
measur
ventil
inhomogen
frc
tidal
breath
nonresid
inert
gase
also
use
lung
clearanc
index
lci
number
lung
volum
express
frc
requir
washout
inert
ga
commonli
use
mbw
index
gener
standard
oper
procedur
techniqu
recent
report
lci
good
feasibl
preschool
children
nearli
lci
success
use
preschool
children
cf
prove
sensit
spirometri
plethysmographi
detect
abnorm
lung
function
howev
longitudin
studi
clinic
util
mbw
preschool
children
lack
data
need
lci
mbw
indic
recommend
routin
clinic
manag
patient
cf
specif
airway
resist
sraw
measur
tidal
breath
preschool
children
use
whole
bodi
plethysmograph
sinc
sraw
product
airway
resist
thorac
ga
volum
calcul
without
need
breath
close
valv
provid
proper
electron
thermal
compens
appli
obviat
need
pant
maneuv
measur
sraw
good
feasibl
young
children
refer
valu
also
avail
howev
lack
consensu
measur
method
outcom
measur
make
difficult
compar
result
among
center
methodolog
techniqu
urgent
need
techniqu
accur
assess
pulmonari
function
possibl
infant
preschool
children
use
number
techniqu
although
techniqu
proven
power
research
tool
studi
need
ascertain
util
clinic
care
infant
young
children
lung
diseas
past
studi
shown
persist
echocardiograph
evid
ph
beyond
first
month
life
associ
mortal
infant
bpd
associ
ph
poor
surviv
bpd
continu
recent
era
new
bpd
especi
infant
sever
diseas
requir
prolong
support
mechan
ventil
thu
develop
insight
pathogenesi
pathobiolog
ph
relat
pulmonari
vascular
diseas
pvd
bpd
continu
import
challeng
may
help
improv
earli
late
cardiopulmonari
outcom
preterm
birth
mechan
coordin
normal
vascular
growth
alveolar
develop
caus
abnorm
lung
growth
bpd
poorli
understood
disrupt
key
signal
airway
epithelium
endotheli
cell
alter
vascular
alveolar
growth
result
decreas
arteri
airspac
structur
exampl
hyperox
lung
injuri
newborn
anim
decreas
express
critic
proangiogen
endotheli
cell
surviv
factor
vascular
endotheli
growth
factor
vegf
earli
impair
vegf
product
inhibit
vascular
growth
impair
endotheli
function
lead
ph
addit
disrupt
angiogenesi
due
advers
antenat
factor
chorioamnion
preeclampsia
matern
smoke
postnat
event
prematur
birth
caus
vascular
injuri
lead
ph
also
impair
distal
lung
growth
ongo
laboratori
studi
suggest
develop
endotheli
cell
play
key
role
regul
coordin
epitheli
growth
distal
airspac
structur
product
critic
angiocrin
nitric
oxid
hepatocyt
growth
factor
vitamin
insulin
growth
other
thu
sinc
angiogenesi
necessari
normal
alveolar
suggest
protect
develop
pulmonari
vasculatur
earli
injuri
may
lower
pvr
improv
ga
exchang
may
enhanc
distal
lung
growth
improv
long
term
outcom
abnorm
pulmonari
circul
sever
bpd
includ
alter
tone
reactiv
structur
growth
caus
right
heart
failur
impair
ga
exchang
pulmonari
edema
decreas
exercis
capac
clinic
problem
physiolog
abnorm
pulmonari
circul
bpd
includ
elev
pulmonari
vascular
resist
pvr
abnorm
vasoreact
evidenc
mark
vasoconstrictor
respons
acut
hypoxia
impair
ga
exchang
due
abnorm
distribut
lung
blood
flow
abnorm
pulmonari
vascular
structur
also
contribut
high
pvr
due
increas
smooth
muscl
cell
hyperplasia
alter
vascular
complianc
caus
increas
product
abnorm
extracellular
matrix
growth
distal
lung
circul
abnorm
infant
sever
bpd
decreas
arteri
growth
angiogenesi
reduc
vascular
surfac
area
impair
ga
exchang
increas
risk
develop
ph
impair
exercis
capac
older
children
promin
bronchial
systemictopulmonari
collater
vessel
note
earli
morphometr
studi
infant
bpd
readili
identifi
mani
infant
cardiac
catheter
although
collater
vessel
gener
small
larg
collater
may
contribut
signific
shunt
blood
flow
lung
caus
edema
need
higher
fio
addit
recent
autopsi
studi
suggest
presenc
strike
intrapulmonari
anastomot
shunt
vessel
link
distal
pulmonari
bronchial
vessel
may
contribut
poor
oxygen
past
clinic
studi
shown
metabol
function
pulmonari
vasculatur
impair
bpd
reflect
lack
pulmonari
clearanc
circul
norepinephrin
passag
lung
may
contribut
left
ventricular
dysfunct
system
hypertens
clinic
studi
recent
shown
earli
echocardiograph
find
pvd
preterm
birth
strongli
associ
develop
sever
bpd
ph
week
correct
age
interestingli
find
associ
wors
respiratori
cours
initi
hospit
also
late
respiratori
outcom
includ
respiratori
exacerb
hospit
need
asthma
medic
ongo
studi
explor
impact
phspecif
drug
therapi
sildenafil
agent
ph
relat
complic
thu
pvd
preterm
infant
bpd
character
alter
lung
vascular
develop
growth
structur
function
preced
onset
measur
ph
pvd
due
disrupt
normal
pulmonari
vascular
develop
associ
preterm
birth
import
determin
pathobiolog
bpd
contribut
significantli
morbid
mortal
exposur
advers
stimuli
antenat
earli
postnat
period
impair
normal
pulmonari
vascular
develop
creat
imbal
risk
resili
factor
recent
studi
reveal
magnitud
ph
preterm
infant
mani
aspect
pvd
remain
understudi
ongo
investig
continu
explor
risk
factor
mechan
diseas
longterm
outcom
prospect
studi
need
definit
establish
standard
clinic
criteria
pvd
ph
bpd
determin
best
method
earli
diagnosi
risk
stratif
diseas
monitor
larger
collabor
studi
improv
clinic
infrastructur
conduct
import
investig
provid
answer
critic
question
recent
evid
suggest
cftr
act
pure
ion
channel
platform
multipl
cellular
signal
pathway
importantli
protein
interactom
wtand
rather
differ
grow
consensu
indirect
measur
avoid
enhanc
degrad
may
restor
function
recent
discov
cftr
orchestr
proteostat
network
influenc
multipl
cellular
function
act
hub
protein
hubdysfunct
model
propos
proteostasi
network
wide
derang
transgen
cf
mice
primari
nasal
epitheli
cell
freshli
collect
cf
patient
bear
either
homozyg
compound
heterozyg
form
two
level
firstli
autophagi
major
mechan
determin
cytoplasm
protein
turnov
block
due
tissu
transglutaminas
mediat
deplet
essenti
autophagyrel
protein
beclin
lead
secondari
accumul
autophag
substrat
secondli
peptid
fragment
releas
proteolyticallycleav
provok
overactiv
pleiotrop
protein
kinas
protein
kinas
turn
contribut
degrad
combin
inhibit
cysteamin
fdaapprov
treatment
cystinosi
overact
overthecount
greentea
flavonoid
epigallocatechingal
egcg
respect
rescu
stabil
function
protein
pm
mice
primari
nasal
cell
cf
patient
bear
class
iicftr
mutat
preclin
evid
transgen
mice
provid
mechanist
proofofconcept
use
combin
proteostasi
regul
altern
cftrrepair
therapi
moreov
combin
treatment
reduc
lung
inflamm
benefici
effect
persist
week
follow
cysteamin
withdraw
provid
egcg
administ
washout
prompt
openlabel
trial
assess
individu
respons
synergist
combin
cysteamin
egcg
cf
patient
bear
differ
cftr
mutat
combin
treatment
well
toler
decreas
sweat
chlorid
baselin
increas
abund
function
cftr
protein
restor
autophagi
nasal
cell
notabl
treatment
decreas
tnfa
sputum
improv
respiratori
function
posit
effect
particularli
strong
patient
carri
class
ii
mutat
homozygos
heterozygos
wherea
patient
class
cftr
mutat
fail
respond
therapi
altogeth
result
suggest
combin
treatment
act
target
accord
hypothesi
underpin
drug
design
discord
therapeut
respons
rate
complic
mutationspecif
approach
thu
entail
need
patientcent
person
approach
assess
drug
efficaci
test
put
individu
respons
treatment
appropri
biomark
vivo
therapi
support
decis
treat
show
restor
cftr
function
vitro
nasal
cell
respons
cysteamin
plu
egcg
highli
predict
whether
combin
treatment
restor
cftr
function
vivo
henc
invitro
assay
may
constitut
tool
guid
clinic
develop
cf
treatment
allow
select
patient
new
therapeut
option
gener
frame
care
infant
cf
must
receiv
care
accredit
cf
care
center
must
review
clinic
frequent
diagnosi
exampl
month
first
month
age
everi
month
year
age
everi
month
thereaft
initi
diagnosi
cf
center
contact
primari
care
profession
regular
ambulatori
followup
implement
therapeut
strategi
parent
infant
cf
offer
access
genet
advic
counsel
standard
childhood
immun
schedul
must
appli
accord
nation
guidelin
antiinfluenza
vaccin
recommend
infant
th
month
life
household
member
healthcar
provid
accord
french
guidelin
vaccin
chicken
pox
could
recommend
growth
target
reflect
genet
potenti
sibl
height
local
popul
demograph
french
guidelin
recommend
catchup
birth
weight
percentil
month
year
weightforheight
th
percentil
height
target
height
percentil
target
height
averag
height
parent
plu
cm
boy
minu
cm
girl
energi
intak
evalu
perform
dietician
regular
basi
adapt
achiev
object
weightforheight
growth
energi
intak
could
much
daili
recommend
calori
intak
age
gener
popul
breast
feed
encourag
recent
data
acknowledg
protect
effect
pseudomona
aeruginosa
infect
formula
hydrolyz
cow
milk
protein
recommend
infant
risk
malabsorpt
sever
undernourish
sodium
chlorid
supplement
systemat
particularli
case
breast
feed
adapt
natriuresi
increas
period
hot
weather
caus
high
salt
loss
diarrhea
fever
ileostomi
etc
initi
diagnosi
infant
must
pancreat
function
assess
stool
fecal
elastas
elastas
normal
repeat
assess
recommend
pancreat
enzym
replac
therapi
start
diagnosi
case
clinic
symptom
exocrin
pancreat
insuffici
even
obtain
result
elastas
assay
start
dose
could
iu
lipas
per
ml
milk
case
persist
symptom
pancreat
insuffici
despit
maximum
dose
uikgday
lipas
may
necessari
evalu
patient
complianc
method
conserv
administr
pancreat
extract
case
poor
weightforheight
growth
despit
adapt
substitut
pancreat
opotherapi
evalu
necessari
includ
dietet
review
search
sodium
insuffici
etiolog
malabsorpt
case
persist
symptom
exocrin
pancreat
insuffici
despit
maximum
dose
uikgday
lipas
absenc
etiolog
administr
gastric
secret
inhibitor
may
envisag
bacteri
cultur
bronchial
flora
perform
session
physiotherapi
case
abnorm
clinic
statu
ideal
bronchial
secret
expector
obtain
sputum
induct
chest
xray
perform
baselin
annual
assess
case
clinic
abnorm
high
resolut
comput
tomographi
complet
assess
case
clinic
radiolog
abnorm
andor
initi
assess
accord
local
practic
detect
earli
bronchiectasi
systemat
respiratori
physiotherapi
recommend
time
diagnosi
frequenc
session
physiotherapi
depend
clinic
statu
infant
regular
therapi
might
recommend
even
asymptomat
infant
evid
respiratori
infect
justifi
perform
respiratori
cultur
adapt
antibiot
treatment
isol
pathogen
infect
staphylococcu
aureu
sensit
meticillin
treat
adapt
antibiotherapi
case
isol
aureu
resist
meticillin
treatment
aim
erad
recommend
evid
p
aeruginosa
justifi
systemat
antibiot
treatment
even
asymptomat
infant
although
still
consensu
treatment
might
begin
inhal
antibiot
eventu
associ
oral
ciprofloxacin
case
persist
p
aeruginosa
initi
therapi
infant
present
sever
clinic
sign
intraven
antibiot
consid
pathogen
less
clear
agreement
treatment
guid
local
polici
absenc
clinic
improv
despit
adapt
antibiotherapi
bronchial
sampl
bronchoalveolar
lavag
consid
noninfecti
caus
search
includ
gastroesophag
reflux
asthma
ent
caus
respiratori
syncyti
viru
rsv
may
advers
effect
respiratori
statu
patient
cf
insuffici
evid
support
systemat
recommend
palivizumab
cf
infant
even
small
studi
suggest
could
benefit
use
rsv
prophylaxi
infant
cf
us
french
guidelin
state
palivizumab
could
discuss
name
infant
less
month
age
epidem
period
final
dornas
alfa
hyperton
salin
might
use
symptomat
infant
increas
number
infant
cf
diagnos
newborn
screen
across
europ
north
america
opportun
larg
cohort
followup
random
control
trial
help
establish
still
lack
best
avail
evid
harmon
therapeut
strategi
infant
newli
diagnos
final
aim
improv
clinic
statu
later
age
depart
pediatr
cf
pcd
center
hadassah
hebrewunivers
medic
center
mount
scopu
jerusalem
israel
eitank
hadassahorgil
bronchiectasi
distract
normal
anatomi
conduct
airway
result
impair
mucociliari
clearanc
lead
chronic
cough
sputum
product
recurr
infect
inflamm
caus
damag
bronchial
bronchiolar
wall
lead
viciou
cycl
airway
injuri
preval
noncf
bronchiectasi
ncfb
children
differ
develop
poor
countri
develop
world
common
caus
bronchiectasi
children
cystic
fibrosi
cf
follow
primari
ciliari
dyskinesia
immun
defici
howev
half
case
remain
without
known
etiolog
develop
countri
systemat
review
children
demonstr
etiolog
identifi
children
previou
sever
pneumonia
bacteri
viral
etiolog
bcell
defect
common
identifi
disord
bronchiectasi
suspect
patient
present
chronic
product
cough
mucopurul
sputum
physic
find
bronchiectasi
patient
nonspecif
may
includ
crackl
wheez
lung
examin
club
digit
pulmonari
function
test
result
gener
show
airflow
obstruct
diagnosi
bronchiectasi
confirm
hrct
scan
gold
standard
diagnosi
includ
bronchial
dilat
intern
bronchial
diamet
greater
diamet
accompani
bronchial
arteri
ie
signet
ring
format
lack
bronchial
taper
sequenti
slice
patient
bronchiectasi
diagnos
evalu
potenti
underli
caus
need
undergo
chest
ct
scan
defin
extent
diseas
patient
focal
diseas
requir
bronchoscopi
evalu
local
airway
obstruct
caus
bronchiectasi
patient
diffus
bronchiectasi
assess
underli
system
abnorm
includ
congenit
disord
chronic
aspir
impair
mucociliari
clearanc
system
local
innat
immun
dysfunct
patient
bronchiectasi
regular
routin
microbiolog
examin
sputum
routin
bacteri
ntm
organ
pulmonari
exacerb
ncfb
known
associ
poor
outcom
infect
common
caus
gramneg
bacteria
isol
frequent
patient
ncfb
h
influenza
p
aeruginosa
repres
major
identifi
speci
howev
sputum
sampl
fail
grow
pathogen
bacteria
patient
sputum
sampl
domin
p
aeruginosa
pa
higher
frequenc
exacerb
poorer
lung
function
compar
patient
whose
sampl
domin
organ
nontubercul
mycobacteria
ntm
opportunist
pathogen
afflict
patient
preexist
lung
diseas
particular
ncfb
shown
metaanalysi
chu
et
al
preval
nearli
patient
respiratori
virus
found
nearli
exacerb
goal
bronchiectasi
treatment
reduc
number
exacerb
improv
qualiti
life
underli
system
etiolog
immun
defici
identifi
address
pharmacolog
agent
mechan
mobil
secret
evalu
limit
degre
patient
noncf
bronchiectasi
shortact
longact
bronchodil
adrenerg
anticholinerg
agent
commonli
prescrib
random
control
trial
support
use
pulmozym
advers
effect
studi
patient
noncf
bronchiectasi
inhal
mannitol
show
improv
time
first
exacerb
qualiti
life
nebul
hyperton
salin
solut
shown
promis
treatment
patient
cf
noncf
bronchiectasi
longterm
prospect
trial
need
role
use
mainten
antibiot
therapi
uncertain
patient
noncf
bronchiectasi
rotat
oral
antibiot
strategi
commonli
use
exacerb
antibiot
therapi
tailor
sputum
microbiolog
result
sever
exacerb
particularli
patient
infect
organ
resist
therapi
oral
quinolon
requir
iv
antibiot
therapi
azithromycin
shown
attenu
gene
express
therebi
suppress
synthesi
mucin
human
airway
epitheli
cell
clinic
demonstr
studi
found
mean
sputum
volum
qol
significantli
lower
patient
bronchiectasi
week
azithromycin
compar
control
subject
recent
random
doubleblind
placebocontrol
trial
adult
assign
patient
receiv
mg
azithromycin
placebo
three
time
week
month
show
azithromycin
significantli
reduc
exacerb
rate
signific
effect
base
studi
recommend
patient
ncfb
treat
azithromycin
longterm
inhal
antibiot
use
patient
uncontrol
ncfb
recent
data
efficaci
lack
use
mechan
aid
includ
chest
physic
therapi
postur
drainag
activ
cycl
breath
oscillatori
posit
expiratori
pressur
devic
high
frequenc
assist
airway
clearanc
also
constitut
potenti
adjunct
therapi
patient
bronchiectasi
though
modal
consid
standard
therapi
patient
cf
bronchiectasi
util
less
well
proven
patient
noncf
bronchiectasi
shown
comprehens
medic
care
children
ncfb
associ
decreas
exacerb
rate
find
exemplifi
import
identifi
ncfb
pediatr
patient
also
ensur
receiv
close
surveil
treatment
burden
lack
immedi
appar
outcom
caus
patient
avoid
daili
therapi
seek
therapi
exacerb
resect
surgeri
lung
transplant
rare
requir
surgic
treatment
classic
option
patient
local
bronchiectasi
persist
symptom
despit
maxim
therapi
recurr
infect
resist
pathogen
prognosi
patient
bronchiectasi
variabl
given
heterogen
natur
diseas
random
control
trial
therapi
noncf
bronchiectasi
patient
must
evalu
treat
individu
basi
tailor
patientfocus
approach
special
center
optim
evalu
treat
individu
bronchiectasi
human
domin
innerv
airway
provid
parasympathet
vagu
nerv
whose
activ
induc
releas
acetylcholin
acetylcholin
primari
parasympathet
neurotransmitt
airway
interact
predominantli
nicotin
receptor
five
muscarin
receptor
subtyp
addit
wellknown
function
ie
bronchoconstrict
mucu
secret
regul
evid
acetylcholin
might
also
modul
inflammatori
cell
chemotaxi
activ
particip
signal
event
lead
airway
wall
remodel
find
signific
implic
anticholinerg
therapi
diseas
character
airway
inflamm
bronchial
obstruct
mucu
hypersecret
sinc
varieti
data
indic
function
muscarin
receptor
alter
patient
nicotin
acetylcholin
receptor
nachr
ligandg
ion
channel
form
five
homolog
ident
subunit
arrang
form
central
ion
channel
depend
subunit
composit
nachr
show
differ
kinet
pharmacolog
properti
lung
tissu
muscl
nachr
local
neuromuscular
junction
smooth
muscl
cell
whilst
neuron
nachr
express
autonom
ganglia
also
almost
everi
cell
type
includ
bronchial
alveolar
epitheli
cell
endotheli
cell
pulmonari
neuroendocrin
cell
submucos
gland
airway
vascular
smooth
muscl
fibroblast
alveolar
macrophag
although
nachr
classic
link
depolar
plasma
membran
requir
neurotransmiss
nonneuron
nachr
lung
act
frequent
calcium
channel
link
regulatori
protein
control
cell
prolifer
function
role
nachr
particularli
complex
depend
subunit
composit
dose
respons
durat
ligand
stimul
although
nachr
activ
often
lead
posit
feedback
loop
induc
receptor
express
chronic
stimul
nachr
produc
channel
desensit
decreas
activ
major
studi
nachr
function
lung
relat
effect
nicotin
ie
tobaccoinduc
mutagenesi
lung
carcinogenesi
whilst
littl
known
physiolog
function
regul
lung
growth
repair
airway
epitheli
cell
prolifer
differenti
electrolyt
transport
muscarin
receptor
belong
larg
famili
g
proteincoupl
receptor
character
seven
transmembran
domain
five
subtyp
identifi
receptor
detect
airway
lung
tissu
mammal
includ
human
almost
airway
lung
cell
type
express
muscarin
receptor
receptor
present
mainli
peripher
lung
tissu
alveolar
wall
express
airway
epitheli
cell
modul
electrolyt
water
secret
goblet
cell
regul
mucu
product
ganglia
facilit
parasympathet
neurotransmiss
receptor
repres
major
popul
larg
airway
receptor
express
neuron
function
autoreceptor
inhibit
releas
acetylcholin
preganglion
nerv
parasympathet
nerv
termin
airway
smooth
muscl
modul
differ
ion
channel
involv
cell
contract
effect
requir
concomit
receptormedi
releas
calcium
intracellular
store
fibroblast
smooth
muscl
receptor
stimul
cell
prolifer
modul
cellular
respons
associ
airway
remodel
receptor
domin
receptor
subtyp
regul
airway
smooth
muscl
contract
mucu
secret
submucos
gland
goblet
cell
receptor
also
favor
airway
smooth
muscl
prolifer
increas
respons
epiderm
growth
factor
plateletderiv
growth
factor
acetylcholin
addit
parasympathet
nerv
also
synthes
releas
larg
number
nonneuron
cell
includ
neuroendocrin
ciliat
basal
secretori
epitheli
cell
act
autocrin
paracrin
signal
molecul
secretori
ciliat
cell
releas
acetylcholin
lumin
periciliari
fluid
wherea
endocrin
basal
cell
secret
acetylcholin
basal
current
knowledg
suggest
local
autoparacrin
product
acetylcholin
epitheli
cell
may
play
role
regul
variou
aspect
innat
mucos
defens
mechan
includ
mucociliari
clearanc
acetylcholin
known
increas
ciliari
beat
frequenc
airway
modul
releas
inflammatori
mediat
cell
receptor
affect
inflammatori
cell
involv
pathogenesi
obstruct
airway
diseas
express
muscarin
receptor
also
shown
inflammatori
cell
includ
macrophag
tand
blymphocyt
mast
cell
neutrophil
eosinophil
cell
muscarin
receptor
appear
involv
cell
prolifer
releas
proinflammatori
mediat
arteri
vein
bronchopulmonari
anastomos
also
express
muscarin
receptor
dilat
respons
acetylcholin
releas
vagal
nerv
stimul
postganglion
nerv
fiber
form
defin
synaps
target
cell
termin
meshwork
call
autonom
plexu
numer
varicos
call
site
transmitt
releas
variabl
rare
close
contact
cell
airway
smooth
muscl
releas
acetylcholin
parasympathet
nerv
termin
airway
appear
complex
prejunct
regulatori
mechan
avail
data
indic
acetylcholin
releas
enhanc
varieti
proinflammatori
mediat
histamin
bradykinin
neuropeptid
b
adrenerg
agent
whist
inhibitori
control
muscarin
autoreceptor
downregul
eicosanoid
pge
opioid
nitric
oxid
adrenerg
agent
activ
receptor
smooth
muscl
appear
spare
even
increas
asthmat
possibl
greater
affin
acetylcholin
bind
site
also
evid
muscarin
receptor
overexpress
upregul
airway
smooth
muscl
disord
character
bronchial
obstruct
hyperrespons
although
acquir
loss
impair
neuron
receptor
function
may
involv
pathogenesi
function
chang
occur
exposur
allergen
infecti
agent
virus
pollut
ozon
result
increas
acetylcholin
releas
parasympathet
nerv
autoreceptor
dysfunct
allerg
asthma
caus
eosinophil
basic
protein
releas
activ
eosinophil
upon
bind
autoreceptor
sialic
acid
act
alloster
antagonist
mechan
earli
recruit
activ
eosinophil
thought
caus
airway
hyperreact
follow
environment
ozon
exposur
contrast
viral
respiratori
infect
purport
induc
bronchial
hyperrespons
differ
mechan
includ
inhibit
receptor
synthesi
mediat
releas
interferong
activ
tlymphocyt
b
product
neuraminidas
determin
function
impair
receptor
activ
cleav
sialic
acid
c
receptor
dysfunct
caus
activ
substanc
p
receptor
overexpress
influenza
parainfluenza
respiratori
syncyti
viru
interestingli
increas
substanc
p
product
report
patient
asthma
gastroesophag
reflux
disord
recogn
vagusmedi
oesophagealtracheobronchi
reflex
pathogenesi
experi
perform
human
corrobor
relev
pathogenesi
autoreceptor
gener
airflow
limit
show
receptor
select
agonist
inhibit
cholinergicinduc
bronchoconstrict
normal
individu
asthmat
patient
defect
autoreceptor
activ
may
also
explain
bronchoconstrict
induc
bblocker
asthma
drug
increas
cholinerg
tone
downregul
action
endogen
catecholamin
b
adrenoceptor
present
cholinerg
nerv
thu
extrem
synthesi
three
muscarin
receptor
subtyp
express
airway
differ
somehow
conflict
function
receptor
facilit
cholinergicinduc
event
includ
bronchoconstrict
mucu
gland
secretori
activ
whilst
receptor
feedback
inhibitori
function
regul
releas
acetylcholin
cholinerg
nerv
end
inform
great
import
understand
activ
three
anticholinerg
agent
use
treat
patient
revers
airway
obstruct
two
ipratropium
oxitropium
bromid
shortact
nonselect
muscarin
antagonist
lack
select
also
block
receptor
increas
acetylcholin
releas
therefor
reduc
degre
use
action
receptor
contrast
recent
longact
anticholinerg
drug
tiotropium
bromid
character
kinet
select
receptor
receptor
dissoci
rapidli
receptor
slowli
receptor
date
anticholinerg
agent
commonli
use
treat
respiratori
disord
childhood
nonselect
ipratropium
bromid
alon
associ
inhal
b
adrenoceptor
agonist
demonstr
significantli
improv
pulmonari
function
clinic
outcom
acut
asthma
preschool
wheez
although
longterm
assess
includ
interestingli
preliminari
data
show
inhal
tiotropium
bromid
daili
well
toler
also
improv
lung
function
pediatr
patient
cystic
fibrosi
asthmat
adolesc
symptomat
despit
inhal
corticosteroid
evid
experiment
model
also
suggest
tiotropium
bromid
may
also
modul
acetylcholineinduc
inflammatori
remodel
chang
induc
airway
varieti
stimuli
lead
hope
favor
clinic
respons
respiratori
disord
relev
role
pathogenesi
obstruct
airway
disord
thought
play
increas
acetylcholin
releas
least
part
due
receptor
dysfunct
commonli
prescrib
shortact
anticholinerg
drug
ipratropium
bromid
select
muscarin
receptor
subtyp
despit
efficaci
common
pediatr
airway
diseas
asthma
preschool
wheez
cystic
fibrosi
ipratropium
bromid
commonli
prescrib
standalon
medic
recent
introduc
anticholinerg
drug
tiotropium
bromid
advanc
pharmacolog
properti
long
durat
action
function
select
receptor
receptor
shown
good
efficaci
safeti
profil
adult
respiratori
disord
asthma
cystic
fibrosi
chronic
obstruct
pulmonari
diseas
ongo
studi
way
defin
therapeut
role
pediatr
airway
diseas
inhal
smoke
datura
strammonium
member
deadli
nightshad
famili
recommend
treatment
asthma
centuri
ayuverd
literatur
gener
gent
asthmat
return
india
earli
centuri
report
brought
therapi
england
strammonium
belladonna
cigarett
wide
use
treat
respiratori
diseas
middl
th
centuri
howev
frequent
side
effect
includ
tachycardia
hallucin
even
addict
introduct
synthet
atropin
deriv
fewer
side
effect
renew
interest
anticholinerg
therapi
asthma
bronchial
smooth
muscl
tone
predominantli
set
cholinerg
activ
patient
asthma
increas
bronchial
smooth
muscl
tone
mucu
hypersecret
like
result
cholinerg
activ
anticholinerg
medic
relax
smooth
muscl
children
acut
asthma
drug
also
appear
antiinflammatori
properti
may
reduc
goblet
cell
hyperplasia
driven
neutrophil
elastas
featur
sever
asthma
known
resist
steroid
therapi
shortact
anticholinerg
agent
ipratropium
bromid
oxitropium
bromid
use
asthma
mani
year
primarili
acut
asthma
emerg
depart
paradox
although
addit
anticholinerg
medic
beta
agonist
decreas
acut
asthma
sever
hospit
admiss
studi
suggest
continu
anticholinerg
patient
hospit
hasten
recoveri
decreas
length
hospit
stay
howev
studi
small
potenti
underpow
past
decad
result
dampen
enthusiasm
studi
anticholinerg
medic
mainten
asthma
therapi
chang
longact
anticholinerg
lama
bronchodil
investig
avail
treat
lung
diseas
includ
tiotropium
aclidinium
glycopyrronium
glycopyrrol
umeclidinium
oncedaili
lama
tiotropium
bromid
demonstr
improv
lung
function
decreas
risk
exacerb
adolesc
adult
moder
sever
asthma
despit
use
inhal
corticosteroid
ic
longact
b
agonist
laba
septemb
fda
unit
state
approv
tiotropium
longterm
mainten
treatment
asthma
patient
year
age
older
tiotropium
respimat
softmist
inhal
includ
global
initi
asthma
report
gina
global
strategi
asthma
manag
prevent
phase
studi
tiotropium
improv
asthma
symptom
enrol
subject
decreas
exacerb
whilst
safeti
profil
similar
placebo
studi
also
show
tiotropium
effect
improv
pulmonari
function
decreas
asthma
attack
children
age
poor
asthma
control
despit
use
medium
dose
ic
without
leukotrien
modifi
differ
effect
compar
fdaapprov
dose
mcg
mcg
daili
tiotropium
higher
dose
mcg
initi
studi
children
younger
year
appear
show
benefit
increas
knowledg
divers
action
cholinerg
system
asthma
role
muscarin
receptor
airway
gain
increas
appreci
anticholinerg
medic
play
import
role
treat
children
adult
chronic
poorlycontrol
asthma
er
task
forc
opt
use
term
asthma
describ
preschool
wheez
ill
sinc
insuffici
evid
show
pathophysiolog
preschool
wheez
ill
similar
asthma
older
age
task
forc
refer
pre
school
wheez
describ
episod
viral
wheez
children
wheez
intermitt
well
episod
versu
multipletrigg
wheez
children
wheez
outsid
discret
episod
therefor
current
discuss
refer
young
age
morbid
entiti
discuss
separ
asthma
acknowledg
much
yet
learn
natur
entiti
amongst
mani
mechan
virusinduc
airway
hyperreact
common
phenomenon
pediatr
practic
relat
young
age
group
studi
shown
cholinerg
overact
modul
substanc
p
may
mediat
virusinduc
airway
hyperreact
virusspecif
lymphocyt
may
induc
cholinerg
activ
receptor
dysfunct
henc
anticholinerg
medic
may
role
viralinduc
wheez
compound
display
select
muscarin
receptor
receptor
advantag
nonselect
compound
number
small
studi
address
role
anticholinerg
acut
bronchiol
fail
show
role
acut
intervent
studi
infant
randomli
assign
receiv
nebul
salbutamol
ipratropium
bromid
placebo
result
faster
improv
clinic
score
oxygen
satur
level
bronchodil
group
placebo
effect
chang
natur
cours
diseas
studi
topic
inhal
ipratropium
bromid
administ
wheezi
children
month
age
improv
lung
function
measur
total
bodi
plethysmographi
forc
oscil
techniqu
author
unabl
differenti
respond
nonrespond
clinic
physiolog
paramet
submit
differenti
distribut
obstruct
small
larg
airway
may
underli
respons
lack
thereof
subject
predomin
larg
airway
obstruct
respond
inhal
ipratropium
logic
unproven
addit
specul
anticholinerg
decreas
airway
secret
reduc
larg
airway
resist
cochran
review
examin
effect
ad
ipratropium
bromid
b
agonist
wheezi
infant
suggest
combin
therapi
improv
symptom
score
hour
compar
use
jb
agonist
alon
er
task
forc
cite
offer
evidencebas
recommend
definit
assess
treatment
wheez
disord
preschool
children
addit
ipratropium
bromid
short
act
b
agonist
suggest
patient
sever
wheez
review
task
forc
recommend
refer
made
use
anticholinerg
medic
tracheobronchomalacia
wide
believ
amongst
pediatr
pulmonologist
administr
b
agonist
infant
airway
structur
instabl
predominantli
tracheobronchomalacia
detriment
use
anticholinerg
bronchodilat
safe
notion
deriv
studi
infant
intrathorac
tracheomalacia
use
infant
pulmonari
function
test
demonstr
flow
improv
significantli
administr
metacholin
worsen
administr
albuterol
result
suggest
patient
abnorm
collaps
trachea
larg
bronchi
stimul
smooth
muscl
improv
airway
stabil
therebi
increas
forc
expiratori
flow
relax
airway
smooth
muscl
bronchodil
exacerb
obstruct
sole
support
observ
come
review
seri
patient
tracheobronchomalacia
chile
betaagonist
medic
discontinu
anticholinerg
effect
anticholinerg
medic
assess
directli
studi
thu
whether
class
medic
may
differ
effect
compar
beta
agonist
patholog
establish
studi
effect
variou
bronchodil
patholog
use
newer
technolog
assess
airway
resist
eg
forc
oscil
undertaken
invas
challeng
techniqu
direct
quantit
assess
tracheal
collaps
infant
tracheomalacia
describ
may
adequ
techniqu
answer
import
clinic
question
tiotropium
bromid
pediatr
use
asthma
asthmacopd
overlap
syndrom
ipratropium
bromid
limit
role
childhood
asthma
larg
due
lack
select
recent
introduc
longact
muscarin
antagonistsanticholinerg
lama
tiotropium
bromid
present
advanc
pharmacolog
properti
select
muscarin
receptor
receptor
long
durat
action
high
safeti
profil
increas
evid
efficaci
render
mainstay
medic
copd
emerg
role
adult
asthma
studi
emerg
role
treatment
childhood
asthma
defin
therapeut
nich
pediatr
airway
diseas
recent
random
control
trial
tiotropium
addon
therapi
adolesc
moder
asthma
significantli
improv
lung
function
safe
well
toler
ad
least
ic
mainten
therapi
studi
pediatr
patient
asthma
chronic
cough
asthma
center
conclud
tiotropium
benefici
distinct
patient
popul
addon
therapi
asthmat
maxim
mainten
medic
altern
highdos
inhal
steroid
patient
experienc
signific
side
effect
patient
bronchorrhea
predomin
symptom
manifest
chronic
product
cough
latter
popul
like
explain
dri
effect
airway
secret
recent
editori
state
approxim
peopl
worldwid
affect
asthma
chronic
obstruct
pulmonari
diseas
copd
regard
two
distinct
diseas
entiti
two
condit
recogn
heterogen
often
overlap
condit
term
asthmacopd
overlap
syndrom
aco
appli
condit
person
clinic
featur
asthma
copd
recent
year
multipl
report
describ
interfac
asthma
copd
publish
recogn
demarc
line
two
entiti
difficult
defin
precis
definit
variou
popul
still
work
obviou
major
patient
adult
earli
recognit
pediatr
popul
view
asthmat
yet
airway
revers
may
constitut
earli
present
overlap
syndrom
mainstay
therapi
copd
longact
inhal
bronchodil
includ
longact
laba
lama
characterist
member
tiotropium
bromid
patient
copd
recogn
equal
effect
reduc
air
trap
relax
airway
smooth
muscl
result
reduc
effect
intrins
cholinerg
tone
therefor
intrigu
specul
better
definit
overlap
syndrom
emerg
pediatr
import
role
tiotropium
like
emerg
particularli
potenti
steroid
spare
medic
peter
sli
ao
mbb
md
dsc
fracp
fer
f
thor
soc
fapsr
fahm
psli
uqeduau
measur
lung
function
major
import
clinic
practic
respiratori
medicin
respiratori
research
much
learn
risk
factor
underli
respiratori
diseas
measur
lung
function
patient
compar
healthi
control
howev
manag
individu
patient
assess
risk
diseas
onset
progress
necessari
know
whether
individu
lung
function
normal
abnorm
year
number
set
norm
equat
produc
individu
research
group
differ
part
world
incorpor
commerciallyavail
spiromet
use
popul
data
collect
situat
far
ideal
especi
norm
equat
mani
decad
old
gli
data
obtain
center
countri
n
howev
could
use
due
lack
data
ethnic
illeg
franc
small
number
miss
data
lack
qualiti
control
factor
data
also
pool
region
data
europ
israel
fev
fvc
vari
ethnic
group
proport
mean
fev
fvc
independ
ethnic
lower
limit
normal
fev
fvc
show
age
depend
differ
male
femal
reach
midchildhood
fall
progress
approxim
year
age
rate
fall
lower
limit
normal
fev
fvc
ident
women
fvc
declin
slowli
male
ratio
fev
fvc
taken
indic
patholog
airflow
limit
howev
proport
healthi
nonsmok
popul
fev
fvc
rise
steadili
year
age
well
gli
refer
equat
predict
lung
function
peopl
individu
countri
given
gli
refer
equat
compil
pool
data
varieti
sourc
one
might
expect
equat
would
provid
good
estim
lung
function
popul
well
repres
pool
data
wherea
may
popul
either
includ
underrepres
pool
data
inde
appear
case
gli
equat
adequ
repres
lung
function
australasian
caucasian
perform
well
adult
brazil
north
africa
madagasca
children
poland
periurban
rural
india
studi
requir
ascertain
wide
gli
refer
equat
appli
constitut
normal
data
import
consider
creat
refer
equat
character
normal
popul
exclud
dataset
use
construct
gli
refer
equat
exclud
ever
smoker
reason
adult
popul
smoke
exclud
equat
design
lung
function
popul
matern
smoke
pregnanc
result
longterm
reduct
lung
function
gener
taken
consider
defin
healthi
popul
healthi
children
often
defin
prior
asthma
hospit
respiratori
problem
born
full
term
birth
weight
kg
asymptomat
time
test
howev
lum
et
al
recent
demonstr
except
clearcut
factor
current
chronic
respiratori
diseas
includ
children
born
prematur
low
birth
weight
prior
asthma
mildli
symptomat
made
littl
differ
refer
equat
increas
generaliz
target
popul
debat
continu
implic
switch
gli
equat
depend
well
gli
equat
repres
lung
function
local
popul
poland
switch
polish
refer
valu
gli
would
see
increas
diagnosi
obstruct
lung
diseas
increas
diagnosi
restrict
lung
diseas
whether
repres
overdiagnosi
gli
underdiagnosi
old
equat
matter
clinic
judgment
impact
parent
children
cystic
fibrosi
like
substanti
famili
tend
focu
lung
function
especi
fev
express
percent
predict
evid
state
child
lung
diseas
chang
number
technic
reason
must
balanc
likelihood
creat
anxieti
clinic
popul
respiratori
symptom
frequent
infant
young
children
special
emphasi
put
symptom
signal
bronchial
obstruct
bronchial
hyperrespons
may
associ
earli
onset
asthma
sinc
earli
sever
research
group
focus
earli
event
develop
asthma
especi
seek
potenti
risk
factor
predict
persist
symptom
structur
chang
bronchial
mucosa
lung
function
impair
children
earli
obstruct
symptom
also
studi
document
eosinophil
inflamm
remodel
particularli
epitheli
basement
membran
thicken
increas
airway
smooth
muscl
mass
consist
present
patient
persist
asthma
interestingli
marker
inflamm
even
initi
remodel
alreadi
describ
children
clinic
diagnosi
asthma
could
confirm
find
support
hypothesi
remodel
late
consequ
long
last
eosinophil
inflamm
may
run
parallel
develop
asthma
even
preced
initi
inflamm
bronchial
mucosa
hypothesi
later
support
research
base
bronchial
biopsi
infant
eosinophil
inflamm
marker
remodel
document
bronchial
mucosa
symptomat
children
earli
second
year
life
recent
studi
abl
show
basement
membran
thicken
could
found
even
young
children
risk
develop
asthma
even
without
histori
recurr
wheez
howev
signific
find
term
long
term
prognosi
still
remain
less
document
known
airway
hyperrespons
infanc
associ
persist
symptom
later
childhood
also
reduc
airway
patenc
birth
shown
link
increas
risk
develop
asthma
sever
bronchial
hyperrespons
age
year
longterm
follow
children
investig
infanc
reassess
later
childhood
far
show
reduc
baselin
lung
function
symptomat
infant
significantli
associ
subsequ
respiratori
morbid
well
need
antiasthma
medic
age
year
addit
usag
inhal
corticosteroid
age
year
also
seem
posit
correl
basement
membran
thicken
increas
number
mast
cell
bronchial
mucosa
bioptic
sampl
taken
earlier
infanc
studi
thu
suggest
earli
morpholog
chang
airway
wall
might
inde
play
role
determin
subsequ
respiratori
morbid
hand
next
followup
children
age
eight
year
posit
correl
current
respiratori
symptom
marker
inflamm
remodel
describ
infanc
longer
found
find
consist
result
followup
group
children
find
signific
correl
lung
function
fev
fvc
measur
preschool
age
basement
membran
thick
measur
earlier
infanc
toddler
age
risk
group
control
group
children
unpublish
data
recent
airway
smooth
muscl
mass
come
center
interest
mani
research
respiratori
medicin
smooth
muscl
hyperplasia
hypertrophi
bronchial
wall
patient
asthma
consid
consist
featur
bronchial
remodel
notabl
possibl
dysfunct
newli
form
smooth
muscl
bundl
deserv
attent
studi
area
urgent
requir
first
work
children
shown
increas
airway
smooth
muscl
mass
bronchial
wall
might
associ
school
age
asthma
late
anoth
studi
describ
neg
correl
airway
respons
age
year
airway
smooth
muscl
mass
infanc
howev
area
airway
remodel
still
remain
poorli
understood
especi
regard
role
childhood
asthma
base
current
avail
data
reduc
lung
function
birth
earli
childhood
appar
associ
persist
symptom
decreas
lung
function
later
life
howev
still
reliabl
confirm
whether
low
lung
function
correl
earli
sign
airway
remodel
longterm
followup
studi
need
pediatr
patient
compris
tissu
biopsi
taken
earli
age
follow
longitudin
longterm
lung
function
monitor
nasal
sinu
diseas
univers
cystic
fibrosi
cf
nasal
sinu
diseas
usual
coexist
refer
sinonas
diseas
sinc
mucosa
sinus
upper
respiratori
tract
mucosa
lower
respiratori
tract
similar
diseas
may
similar
locat
sinonas
diseas
could
influenc
sever
pulmonari
diseas
view
univers
airway
demonstr
patient
pulmonari
condit
asthma
copd
diseas
improv
sinu
health
reflect
improv
lower
airway
diseas
well
studi
cf
implic
relationship
combin
increas
life
span
make
understand
sinonas
diseas
import
care
patient
mutat
cystic
fibrosi
transmembran
conduct
regul
cftr
gene
cf
carrier
appear
independ
associ
higher
preval
sinonas
diseas
carrier
report
chronic
rhinosinus
compar
gener
popul
bacteri
flora
sinus
chang
patient
age
includ
anaerob
fungi
often
mirror
organ
present
lower
respiratori
tract
link
sinu
infect
lower
respiratori
tract
infect
may
contribut
morbid
follow
lung
transplant
immunosuppress
somewhat
surprisingli
preval
otiti
media
cf
appear
greater
agematch
gener
popul
endoscopi
computer
tomographi
broaden
understand
cf
affect
sinus
endoscop
sinu
exam
almost
alway
abnorm
give
better
indic
presenc
nasal
polyposi
physic
examin
nose
alon
nasal
polyp
becom
common
age
may
repres
prolif
airway
repair
mechan
sinu
ct
demonstr
sever
anomali
characterist
sinonas
diseas
cf
bulg
displac
later
nasal
wall
deminer
uncin
process
hypoplasia
aplasia
paranas
sinus
seriou
complic
sinonas
diseas
cf
rare
includ
mucocel
periorbit
abscess
usual
requir
surgeri
random
control
trial
evalu
medic
surgic
treatment
cf
sinu
diseas
sinu
surgeri
may
provid
benefit
though
establish
select
criteria
appropri
candid
trend
today
neonat
intens
care
unit
nicu
gentl
less
invas
possibl
care
neonat
attitud
take
place
everi
field
neonatolog
discuss
implement
specif
respiratori
care
administ
prematur
infant
respiratori
distress
syndrom
rd
prenat
corticosteroid
therapi
recommend
pregnanc
threaten
preterm
labor
week
gestat
recent
shown
therapi
could
also
benefici
late
preterm
infant
significantli
reduc
rate
neonat
composit
respiratori
treatment
first
hour
stillbirth
neonat
death
within
hour
deliveri
deliveri
term
stabil
resuscit
prefer
vast
major
preterm
infant
minor
babi
requir
deliveri
room
intub
neopuff
help
deliveri
room
transport
nicu
enabl
administr
continu
posit
airway
pressur
cpap
intermitt
posit
pressur
ventil
control
condit
recent
larg
trial
reflect
current
practic
includ
greater
util
matern
steroid
routin
post
deliveri
stabil
ncpap
demonstr
less
risk
bronchopulmonari
dysplasia
bpd
death
use
earli
stabil
ncpap
select
surfact
administr
infant
requir
intub
comprehens
strategi
prevent
bpd
nicu
base
ventilatori
nonventilatori
measur
ventilatori
rout
allow
individu
endotrach
intub
approach
recent
studi
conclud
earli
nasal
cpap
ncpap
safe
altern
immedi
intub
even
extrem
low
birth
weight
elbw
infant
endotrach
intub
ventil
result
signific
damag
prematur
lung
independ
associ
cerebr
palsi
furthermor
despit
new
mode
ventil
surfact
bpd
remain
signific
morbid
incid
correl
use
length
endotrach
mechan
ventil
bpd
associ
advers
neurodevelopment
outcom
thu
need
avoid
endotrach
ventil
possibl
infant
requir
nasal
respiratori
support
nr
aim
adequ
oxygen
spo
permiss
hypercapnia
paco
mm
hg
ph
gentl
ventil
similarli
endotrach
ventil
ncpap
recommend
earli
primari
treatment
activ
respiratori
distress
syndrom
rd
avoid
intub
part
insur
intub
surfact
extub
approach
later
post
extub
rd
resolut
order
allow
shorten
durat
endotrach
ventil
treat
apnea
prematur
recent
studi
report
compar
rate
bpd
elbw
infant
treat
initi
ncpap
compar
endotrach
ventil
surfact
administr
enhanc
ncpap
get
better
outcom
nr
use
nasal
intermitt
posit
pressur
ventil
nippv
nippv
defin
method
augment
ncpap
deliv
ventil
breath
via
nasal
prong
rational
behind
use
nippv
administr
sigh
infant
thu
open
microatelectasi
recruit
ventil
unit
shown
synchron
nippv
snippv
compar
ncpap
may
improv
patenc
upper
airway
could
activ
respiratori
drive
improv
thoracoabdomin
synchroni
stabil
chest
wall
improv
lung
mechan
decreas
work
breath
prematur
infant
nippv
compar
ncpap
differ
indic
nr
shown
enhanc
potenti
nr
recent
metaanalysi
demonstr
rel
risk
reduct
intub
first
hour
nippv
group
compar
ncpap
rr
ci
nippv
trial
larg
intern
multicent
random
trial
power
studi
import
outcom
bpd
recruit
extrem
low
birth
weight
babi
show
differ
babi
random
nippv
compar
cpap
snippv
vs
ncpap
later
use
post
extub
rd
resolut
bridg
spontan
unsupport
breath
shown
effect
ncpap
pool
metaanalysi
show
snippv
effect
ncpap
prevent
failur
extub
rr
number
need
treat
infant
prevent
one
extub
failur
snippv
vs
ncpap
post
extub
also
tend
decreas
rate
bpd
snippv
may
also
effect
ncpap
apnea
prematur
metaanalysi
regard
apnea
prematur
suggest
snippv
efficaci
apnea
frequent
sever
howev
studi
perform
address
shortterm
outcom
could
properli
address
incid
requir
reintub
thu
studi
need
recommend
snippv
standard
care
apnea
prematur
noninvas
ventil
probabl
safe
success
depend
gestat
age
data
indic
surfact
may
still
signific
role
treatment
rd
especi
elbw
infant
recent
studi
report
intub
rate
ncpap
group
elbw
infant
lead
us
insur
approach
approach
may
allow
infant
benefit
surfact
nr
cochran
review
conclud
insur
approach
ncpap
compar
later
select
surfact
administr
continu
mechan
ventil
extub
low
respiratori
support
associ
less
need
mechan
ventil
lower
incid
bpd
fewer
air
leak
syndrom
anoth
option
surfact
applic
trachea
without
endotrach
intub
describ
use
thin
cathet
spontan
breath
preterm
infant
receiv
ncpap
techniqu
report
reduc
need
mechan
ventil
ongo
trial
inhal
surfact
summar
ncpap
still
common
mode
non
invas
respiratori
support
worldwid
avail
evid
support
prefer
earli
later
use
nippvsnippv
compar
ncpap
minim
use
length
endotrach
ventil
data
suggest
approach
may
also
reduc
rate
bpd
howev
yet
shown
result
larg
intern
rct
compar
primari
postextub
use
nippv
ncpap
composit
primari
outcom
death
bpd
week
correct
age
indic
addit
benefit
risk
confer
nippv
comparison
ncpap
whether
nippvsnippv
benefici
ncpap
within
insur
approach
need
shown
recent
heat
humidifi
highflow
nasal
cannula
hhhfnc
frequent
use
mode
nr
high
flow
result
washout
anatom
physiolog
dead
space
contribut
improv
fraction
alveolar
gase
respect
carbon
dioxid
well
oxygen
decreas
work
breath
energi
cost
ga
condit
hhhfnc
probabl
creat
posit
end
expiratori
pressur
peep
may
contribut
benefici
effect
howev
peep
monitor
rais
concern
regard
safeti
hhhfnc
term
air
leak
recent
prospect
studi
support
notion
hhhfnc
effect
ncpap
earli
stage
rd
post
extub
apnea
prematur
yet
studi
especi
initi
treatment
rd
elbw
infant
need
adopt
hhhfnc
altern
mode
nr
condit
new
mode
nr
neural
adjust
ventil
assist
nava
nasal
high
frequenc
ventil
need
studi
conclud
benefit
short
long
term
outcom
prematur
infant
nonventilatori
measur
treatment
rd
caffein
nutrit
fluid
pda
manag
postnat
steroid
certain
condit
includ
care
prematur
infant
rd
order
minim
rate
bpd
noninvas
ventil
strategi
need
confirm
larg
prospect
random
control
trial
longterm
follow
order
assur
applic
elbw
infant
furthermor
strategi
need
tailor
individu
infant
accord
infant
matur
antenat
steroid
treatment
sever
rd
gener
condit
certain
practic
nicu
condit
experi
personnel
time
day
mani
year
gener
accept
pathophysiolog
rsv
bronchiol
driven
inflammatori
respons
evok
horizont
ie
interperson
transmiss
viru
first
month
birth
howev
recent
publish
studi
brought
forefront
strike
new
idea
rsv
may
transmit
vertic
respiratori
tract
mother
lung
fetu
believ
pregnant
woman
got
cold
develop
fetu
protect
placenta
rsv
respiratori
virus
studi
pregnant
rat
inocul
recombin
rsv
strain
could
track
express
red
fluoresc
protein
rrrsv
viru
subsequ
found
percent
fetus
expos
utero
well
lung
percent
newborn
rat
percent
rat
born
inocul
mother
test
adulthood
data
provid
proof
concept
transplacent
transmiss
rsv
mother
offspr
persist
vertic
transmit
viru
lung
birth
notabl
intrauterin
rsv
infect
chang
express
function
critic
neurotroph
pathway
control
develop
cholinerg
nerv
bud
airway
lung
tissu
chang
cholinerg
innerv
fetal
respiratori
tract
result
develop
postnat
airway
hyperreact
upon
reinfect
viru
airway
smooth
muscl
tone
normal
absenc
stimul
contract
normal
absenc
either
matern
neonat
infect
pup
reinfect
rsv
prenat
exposur
viru
markedli
potenti
contractil
respons
measur
either
electr
nerv
stimul
methacholin
inhal
suggest
involv
preand
postjunct
mechan
find
consist
provid
plausibl
mechan
epidemiolog
evid
earlylif
rsv
infect
possibl
reinfect
predispos
subpopul
children
recurr
wheez
asthma
typic
span
first
decad
life
even
absenc
atop
phenotyp
knowledg
first
report
vertic
transmiss
rsv
matter
common
respiratori
viru
number
infecti
agent
includ
herpesvirus
retrovirus
shown
cross
placenta
establish
persist
infect
offspr
new
evid
extend
possibl
infect
rsv
regard
temporari
local
instead
may
longer
last
pervas
thought
also
shown
viral
pathogen
rsv
seed
fetu
full
tcell
matur
could
lead
induct
prenat
toler
justifi
limit
synthesi
interferon
inflammatori
cytokin
note
newborn
develop
sever
infect
vertic
rsv
asthma
gener
concept
work
decad
noth
bad
happen
lung
babi
born
even
seriou
condit
cystic
fibrosi
lung
clean
pathogen
birth
human
studi
replic
find
anim
model
outlin
understand
pathogenesi
rsv
infect
would
complet
chang
would
turn
back
clock
respiratori
development
diseas
month
mean
would
need
start
think
lung
develop
patholog
pregnanc
rather
birth
could
creat
paradigm
shift
extend
focu
prevent
first
year
birth
also
includ
last
month
birth
new
paradigm
line
emerg
evid
mani
chronic
inflammatori
degen
even
neoplast
diseas
plagu
adult
origin
oftensubtl
event
occur
fetal
life
foetal
program
hypothesi
origin
formul
dr
david
barker
two
decad
ago
explain
extens
reproduc
confirm
epidemiolog
evid
low
birth
weight
predispos
cardiovascular
diseas
late
adulthood
dr
barker
die
age
septemb
leav
legaci
initi
controversi
wide
accept
idea
common
chronic
ill
cancer
cardiovascular
diseas
diabet
result
alway
bad
gene
unhealthi
adult
lifestyl
poor
intrauterin
earli
postnat
health
one
last
public
speech
argu
next
gener
suffer
heart
diseas
osteoporosi
diseas
mandat
human
genom
bare
exist
year
ago
unnecessari
diseas
could
prevent
believ
concept
extend
chronic
obstruct
airway
diseas
like
asthma
copd
asthma
final
product
complex
interact
genet
environment
variabl
prenat
event
like
intrauterin
exposur
virus
specif
tropism
develop
respiratori
epithelium
imbalanc
matern
diet
caus
shift
trajectori
structur
function
airway
develop
toward
hyperreact
phenotyp
intrauterin
exposur
affect
gene
express
via
epigenet
modif
like
dna
methyl
histon
acetyl
alter
rel
express
regulatori
microrna
result
neonat
phenotyp
predispos
child
aberr
respons
common
respiratori
infect
airborn
irrit
therebi
increas
risk
obstruct
lung
diseas
later
life
postnat
event
exposur
indoor
outdoor
pollut
allergen
shift
equilibrium
adult
phenotyp
exacerb
airway
inflamm
hyperreact
continu
rang
possibl
development
trajectori
multipl
sequenti
event
act
develop
defin
sever
durat
diseas
incid
sever
mortal
childhood
pneumonia
declin
substanti
last
decad
due
improv
socioeconom
condit
better
access
care
wider
implement
effect
manag
prevent
strategi
develop
avail
improv
vaccin
particularli
pneumococc
pcv
h
influenza
type
b
hib
conjug
vaccin
howev
pneumonia
remain
lead
caus
childhood
mortal
global
outsid
neonat
period
major
caus
morbid
hospit
despit
good
immun
coverag
earli
childhood
pneumonia
increasingli
associ
develop
chronic
noncommunic
respiratori
diseas
childhood
adulthood
asthma
chronic
obstruct
airway
diseas
copd
improv
global
coverag
newer
conjug
vaccin
like
viral
caus
pneumonia
may
respons
increas
proport
pneumonia
case
howev
defin
etiolog
pneumonia
may
challeng
difficult
distinguish
colon
pathogen
organ
respiratori
specimen
blood
cultur
rare
posit
pneumonia
especi
sever
diseas
may
frequent
due
multipl
copathogen
develop
better
method
specimen
collect
molecular
diagnost
provid
sensit
techniqu
defin
potenti
etiolog
agent
compound
difficulti
ascrib
pathogen
despit
limit
studi
postpcv
era
report
increas
predomin
virus
childhood
pneumonia
case
viru
identifi
case
children
vaccin
pcv
rsv
report
predomin
pathogen
case
control
analys
high
incom
countri
lowmiddl
countri
set
howev
frequent
cooccurr
potenti
pathogen
rsv
includ
bacteria
virus
children
month
age
highest
risk
rsv
diseas
adequ
interpret
data
virus
context
childhood
pneumonia
preval
healthi
control
children
must
consid
use
case
control
design
virus
identifi
associ
pneumonia
rsv
influenza
viru
human
metapneumoviru
hmpv
adenoviru
parainfluenza
viru
coronaviru
variabl
associ
pneumonia
preval
rhinoviru
consist
similar
case
control
use
quantit
measur
viral
load
shown
use
distinguish
case
control
except
rsv
hmpv
presenc
alon
suffici
ascrib
etiolog
studi
indic
rsv
major
caus
pneumonia
era
conjug
vaccin
bacteri
pathogen
particularli
young
infant
howev
also
highlight
limit
current
diagnost
strategi
particularli
poor
sensit
current
test
bacteri
etiolog
potenti
incorrectli
assign
etiolog
base
molecular
diagnost
also
provid
data
complex
ascrib
pneumonia
etiolog
show
interact
multipl
potenti
pathogen
despit
limit
emerg
data
indic
key
strategi
reduc
burden
childhood
pneumonia
lie
prevent
rsv
diseas
young
children
identifi
etiolog
pneumonia
key
initi
appropri
manag
strategi
particularli
use
antibiot
guid
develop
new
vaccin
reduct
bacteri
pneumonia
conjug
vaccin
underscor
need
reconsid
empir
treatment
pneumonia
set
strong
immun
program
case
manag
antibiot
pneumonia
sever
pneumonia
world
health
organ
integr
manag
childhood
ill
imci
program
highli
effect
strategi
reduc
mortal
prior
widespread
conjug
vaccin
avail
defin
residu
burden
identifi
clinic
laboratori
featur
distinguish
bacteri
viral
pathogen
import
chang
pneumonia
strategi
recommend
global
late
preterm
lp
newborn
born
week
gestat
age
compris
fastest
grow
subset
neonat
account
approxim
preterm
birth
total
birth
us
late
preterm
infant
born
near
term
immatur
late
prematur
birth
interrupt
normal
utero
fetal
develop
last
week
gestat
probabl
critic
period
growth
develop
fetal
lung
three
factor
play
role
respiratori
vulner
lp
infant
prematur
development
consequ
physiolog
compon
heighten
rate
respiratori
morbid
neonat
period
shortterm
pulmonari
outcom
respiratori
complic
prime
morbid
lp
infant
larg
retrospect
studi
found
odd
respiratori
morbid
respiratori
distress
syndrom
rd
transient
tachypnea
newborn
ttn
pneumonia
respiratori
failur
surfact
administr
mechan
ventil
decreas
significantli
advanc
week
gestat
week
compar
week
despit
rel
low
absolut
risk
rd
ttn
week
compar
prematur
infant
rate
pose
increas
risk
lp
infant
compar
term
infant
acknowledg
morbid
led
studi
aim
decreas
burden
recent
larg
random
control
studi
show
administr
betamethason
women
risk
late
preterm
deliveri
significantli
reduc
rate
neonat
composit
respiratori
treatment
first
hour
use
continu
posit
airway
pressur
highflow
nasal
cannula
least
hoursr
supplement
oxygen
fraction
inspir
oxygen
least
least
hour
extracorpor
membran
oxygen
mechan
ventil
stillbirth
neonat
death
within
hour
deliveri
note
neonat
hypoglycemia
common
betamethason
group
placebo
group
late
prematur
may
affect
respiratori
system
long
term
sever
studi
report
associ
preterm
birth
week
ga
without
clinic
lung
diseas
alter
lung
develop
function
friedrich
et
al
longitudin
studi
found
despit
normal
lung
volum
healthi
preterm
infant
persist
reduc
airflow
age
month
conclud
preterm
birth
associ
alter
lung
develop
singl
studi
show
potenti
improv
especi
larg
airway
function
advanc
age
recent
larg
prospect
cohort
studi
show
number
hospit
caus
respiratori
problem
first
year
life
doubl
moderatelyl
preterm
week
ga
compar
term
infant
preschool
age
moder
preterm
infant
reveal
nocturn
cough
wheez
without
cold
increas
use
inhal
steroid
age
year
rate
respiratori
symptom
moder
earli
preterm
born
week
ga
children
similar
higher
term
born
children
whether
lp
birth
associ
airway
diseas
asthma
earli
childhood
remain
controversi
differ
find
publish
studi
could
result
differ
method
asthma
diagnosi
age
group
diagnosi
difficulti
diagnos
asthma
earli
childhood
recent
studi
found
late
preterm
birth
histori
independ
associ
childhood
asthma
year
age
lp
infant
vulner
viral
respiratori
infect
particularli
rsv
sever
infant
vs
term
infant
pernici
combin
rsv
bronchiol
affect
priori
compromis
lung
airway
lp
infant
may
last
effect
respiratori
function
consequ
longterm
morbid
longterm
persist
earli
decreas
pulmonari
function
test
pft
demonstr
longitudin
followup
earli
adulthood
unselect
random
popul
tucson
children
respiratori
studi
observ
suggest
notion
critic
development
period
respiratori
system
exist
deficit
lung
function
earli
life
especi
associ
lower
respiratori
ill
especi
rsv
increas
risk
chronic
obstruct
pulmonari
diseas
later
adult
life
summari
lp
infant
born
critic
development
time
period
lung
may
result
short
longterm
pulmonari
consequ
addit
screen
popul
highrisk
diseas
therefor
effect
earli
case
find
prioriti
depend
sever
factor
health
care
system
contact
trace
laboratori
diagnosi
diagnosi
tb
children
common
clinic
challeng
reli
care
assess
histori
exposur
clinic
examin
relev
investig
recommend
approach
diagnosi
tb
children
adult
base
guidelin
recommend
tabl
import
factor
consid
children
suspect
tb
endem
set
well
age
immun
statu
child
countri
low
incid
tb
posit
contact
case
combin
suggest
symptom
make
diagnosi
straightforward
high
tb
endem
area
histori
tb
contact
remain
import
much
less
sensit
given
transmiss
often
occur
unknown
sourc
case
laboratori
test
diagnosi
infect
group
two
group
detect
microb
compon
detect
compon
immun
respons
microb
sensit
first
group
depend
qualiti
specimen
concentr
microorgan
group
includ
microscopi
cultur
elisa
nucleic
acid
detect
pcr
second
group
measur
activ
immun
system
microbespecif
antigen
possibl
infect
host
categori
includ
antibodi
detect
activ
cell
gold
standard
diagnosi
tb
bacillari
detect
smear
cultur
adult
microscopi
detect
cultureposit
sampl
children
work
well
due
limit
access
appropri
bodi
specimen
also
children
usual
paucibacillari
diseas
sinc
cavit
diseas
rare
children
studi
shown
best
circumst
acidfast
bacilli
sputum
smear
posit
children
tb
cultur
give
better
yield
recent
diagnosi
ltbi
base
exclus
tst
rel
poor
sensit
specif
despit
limit
remain
standard
care
diagnosi
ltbi
worldwid
particularli
lowincom
countri
interferon
gamma
releas
assay
igra
measur
vitro
respons
specif
tuberculosi
antigen
although
offer
sever
advantag
tst
better
specif
singl
visit
littl
interobserv
variabl
boot
effect
found
better
tst
abl
predict
risk
infect
individu
develop
activ
tb
diseas
given
increas
cost
replac
tst
igra
public
health
intervent
resourceconstrain
set
recommend
novel
approach
confirm
tb
develop
includ
method
base
rapid
cultur
techniqu
genotyp
techniqu
improv
detect
tuberculosi
exampl
xpert
mtbrif
assay
fulli
autom
realtim
dna
base
test
detect
tb
rifampicin
resist
less
two
hour
expect
use
rather
convent
microscopi
cultur
children
suspect
mdrtb
clinic
diagnosi
primari
tb
children
remain
challeng
nonspecif
sign
symptom
difficulti
acquir
diagnost
specimen
diagnosi
primari
tb
practic
reli
combin
clinic
featur
chest
xray
cxr
find
detect
lymphadenopathi
hilar
paratrach
region
frontal
cxr
support
identif
subcarin
lymphadenopathi
later
cxr
repres
use
surrog
marker
tb
rel
low
cost
howev
sensit
specif
identifi
lymphadenopathi
cxr
children
rel
poor
signific
interobserv
variat
interpret
radiograph
complic
poor
qualiti
radiograph
affect
accuraci
observ
agreement
lack
standard
imag
criteria
lymph
node
sizecriteria
posit
diagnosi
primari
tb
attempt
therefor
made
establish
object
chest
radiograph
sign
back
standard
set
imag
guid
ultrasound
especi
attract
imag
altern
cxr
involv
radiat
requir
sedat
rel
cheap
mobil
ultrasound
mediastinum
use
detect
mediastin
lymphadenopathi
also
use
detect
extrapulmonari
tb
abdomin
imag
sit
particularli
use
rural
set
imag
avail
abil
store
digit
ultrasound
imag
cineloop
also
enabl
teleradiolog
support
expert
interpret
opinion
distanc
comput
tomographi
ct
magnet
reson
imag
mri
obviou
diagnost
imag
consider
improv
diagnost
accuraci
primari
tb
radiat
dose
ct
need
anesthesia
mri
limit
avail
high
cost
real
barrier
clinic
util
mri
prefer
ct
involv
ioniz
radiat
howev
disadvantag
mri
lung
imag
poor
signal
gener
air
lung
movement
artefact
breath
cost
requir
child
keep
still
prolong
period
requir
anesthesia
slow
use
thorac
infect
yet
whole
bodi
mri
includ
thorac
imag
mainstream
detect
lymphadenopathi
childhood
lymphoma
prefer
imag
techniqu
vari
suspect
patholog
avail
equip
dynam
imag
techniqu
inspiratori
expiratori
cxr
fluoroscopi
inspiratoryexpiratori
cine
ct
permit
lung
airway
imag
differ
phase
respiratori
cycl
inspiratoryexpiratori
cxr
inspiratoryexpiratori
chest
ct
long
prefer
initi
imag
method
detect
foreign
bodi
aspir
bronchiol
obliteran
respect
basi
air
trap
rather
direct
visual
airway
obstruct
fluoroscopi
histor
prefer
noninvas
method
diagnos
tracheobronchomalacia
due
eas
perform
even
uncoop
patient
high
specif
limit
subject
interpret
low
sensit
poor
depict
paratrach
structur
inabl
simultan
display
anteroposterior
later
wall
airway
quantifi
lumin
crosssect
area
infant
children
young
compli
breathhold
instruct
inspiratoryexpiratori
phase
simul
imag
rightleft
later
decubitu
pronesupin
posit
controlledventil
ct
sedat
anesthesia
also
permit
inspiratoryexpiratori
imag
lung
airway
uncoop
patient
dynam
cine
ct
techniqu
allow
airway
imag
sequenti
success
phase
respiratori
cycl
coverag
initi
limit
short
cm
less
segment
airway
result
sampl
misregistr
prevent
synchron
evalu
true
extent
sever
airway
collaps
phase
respiratori
cycl
made
possibl
recent
technolog
advanc
includ
rapid
gantri
rotat
wider
detector
array
cm
craniocaud
coverag
dynam
volumetr
cine
ct
allow
nearli
lung
central
airway
imag
rapidli
sequenti
throughout
respiratori
cycl
without
need
sedat
intub
techniqu
capabl
provid
multiplanar
inform
airway
normal
tidal
breath
forc
expiratori
maneuv
well
depict
relationship
airway
adjac
vasculatur
intraven
contrast
administ
dynam
volumetr
cine
ct
intrins
extrins
caus
airway
narrow
distinguish
fix
airway
stenosi
differenti
expiratori
central
airway
collaps
due
tracheobronchomalacia
soften
tracheobronchi
cartilag
excess
dynam
airway
collaps
inward
bulg
posterior
membran
tracheobronchomalacia
primari
congenit
approxim
children
often
resolv
isol
mild
moder
case
year
age
cartilag
geometri
composit
matur
posterior
membran
tone
develop
tracheobronchomalacia
often
accompani
gastroesophag
reflux
diseas
associ
foregut
anomali
especi
esophag
atresia
tracheoesophag
fistula
tracheobronchomalacia
secondari
extrins
compress
chronic
airway
inflamm
intub
posit
pressur
ventil
identifi
onefourth
children
chronic
respiratori
symptom
sign
wheez
bark
cough
recurr
respiratori
tract
infect
apnea
cyanot
spell
difficulti
wean
respiratori
support
tracheobronchomalacia
origin
defin
reduct
airway
crosssect
diamet
cough
fals
posit
common
definit
especi
bronchi
physiolog
expiratori
airway
narrow
pronounc
trachea
shape
crosssect
area
airway
lumen
precis
determin
ct
current
consensu
optim
threshold
degre
expiratori
airway
collaps
diagnosi
tracheobronchomalacia
among
children
vari
age
without
coexist
lung
diseas
either
tidal
breath
forc
expir
expiratori
collaps
normal
airway
occur
set
obstruct
lung
diseas
asthma
bronchopulmonari
dysplasia
due
increas
pleural
pressur
increas
peripher
airway
resist
reduc
airway
transmur
pressur
dynam
volumetr
cine
ct
provid
object
inform
classifi
expiratori
central
airway
collaps
accord
femo
function
statu
extent
morpholog
origin
sever
system
note
degre
lumin
narrow
one
factor
airflow
limit
evid
airway
compress
expiratori
collaps
imag
necessarili
indic
condit
requir
therapeut
intervent
correl
clinic
symptom
sign
risk
factor
pulmonari
function
test
necessari
determin
function
signific
addit
noninvas
natur
advantag
dynam
volumetr
cine
ct
bronchoscopi
includ
abil
directli
evalu
vascular
structur
soft
tissu
mass
imping
airway
depict
airway
distal
narrow
impass
bronchoscop
assess
lung
parenchyma
condit
air
trap
may
associ
dynam
central
airway
collaps
disadvantag
ct
exposur
ioniz
radiat
perspect
dynam
airway
ct
incur
radiat
dose
similar
less
year
natur
background
radiat
exposur
dynam
cine
magnet
reson
imag
mri
avoid
exposur
ioniz
radiat
capabl
imag
central
airway
vasculatur
limit
longer
scan
time
frequent
need
sedationanesthesia
less
detail
depict
lung
parenchyma
compar
ct
addit
studi
children
need
determin
anatom
function
inform
provid
dynam
ct
best
appli
diagnosi
treatment
plan
posttherapeut
monitor
pediatr
airway
disord
main
drive
forc
develop
sophist
mri
sequenc
pediatr
chest
imag
mri
radiationfre
techniqu
especi
import
children
sensit
ioniz
radiat
adult
justifi
use
chest
mri
shortand
longterm
followup
chronic
lung
diseas
cystic
fibrosi
cf
reduc
lifelong
cumul
radiat
dose
chest
mri
challeng
magnet
heterogen
environ
chest
region
lung
parenchyma
low
proton
densiti
structur
henc
reduc
signaltonois
ratio
addit
numer
airtissu
interfac
within
voxel
induc
strong
local
microscop
magnet
field
gradient
produc
extens
mri
signal
dephas
lead
extrem
short
star
geometr
distort
effect
becom
stronger
higher
magnet
field
strength
ie
increasingli
use
clinic
set
enhanc
signaltonois
ratio
howev
signaltonois
ratio
case
lung
patholog
pneumonia
edema
tumor
atelectasi
increas
higher
fluid
content
amount
tissu
condit
result
higher
proton
densiti
improv
visual
moreov
mri
advantag
integr
anatom
function
inform
singl
examin
possibl
readili
avail
imag
modal
mri
provid
function
inform
regard
lung
perfus
use
gadolinium
contrast
lung
mechan
use
dynam
acquisit
ventil
use
inhal
hyperpolar
gase
oxygen
enhanc
dynam
motionbas
method
moreov
dwi
abl
give
new
insight
manag
pneumonia
especi
cf
patient
chest
mri
reach
point
use
routin
clinic
practic
although
mri
yet
compar
ct
anatom
detail
new
sequenc
allow
acquisit
lung
imag
high
diagnost
qualiti
less
make
mri
feasibl
clinic
set
mri
consid
altern
ct
diagnosi
lung
diseas
monitor
respons
treatment
pediatr
lung
diseas
moreov
diseas
requir
longterm
followup
cystic
fibrosi
mri
play
import
role
reduc
lifelong
radiat
exposur
relat
repeat
ct
scan
furthermor
mri
abil
offer
function
inform
inform
regard
lung
mechan
perfus
ventil
provid
new
insight
differ
pediatr
lung
diseas
function
inform
improv
understand
regard
pathophysiolog
pediatr
lung
diseas
also
open
new
diagnost
therapeut
option
obstruct
sleep
apnea
syndrom
osa
character
prolong
partial
airway
obstruct
andor
intermitt
complet
obstruct
obstruct
apnea
sleep
affect
children
osa
complex
syndrom
multipl
etiolog
factor
main
caus
factor
adenotonsillar
hypertrophi
condit
craniofaci
dysmorph
obes
hypoton
neuromuscular
diseas
despit
induc
reduct
calib
upper
airway
commonli
mistreat
adenotonsillectomi
consid
mani
year
treatment
children
osa
although
efficaci
remain
uncertain
depend
sever
presenc
comorbid
sinc
residu
osa
report
larg
proport
children
adenotonsillectomi
children
osa
display
complex
phenotyp
mild
major
craniofaci
anomali
andor
comorbid
obes
andor
adenotonsillar
enlarg
multitherapeut
approach
pediatr
osa
defin
time
therapi
requir
narrow
upper
airway
accompani
maxillari
constrict
mandibular
retrus
commonli
report
children
osa
skelet
conform
show
hyperdiverg
skelet
growth
pattern
associ
posterior
displac
tongu
base
increas
upper
airway
narrow
craniomandibular
intermaxillari
goniac
mandibular
angl
lead
higharch
ogiv
palat
rapid
maxillari
expans
rme
common
dentofaci
orthoped
procedur
use
young
patient
treat
maxillari
transvers
defici
start
year
age
recent
demonstr
efficaci
treat
osa
children
narrow
palat
malocclus
signific
reduct
apneahypopnea
index
diurnal
symptom
six
month
therapi
rme
posit
longterm
effect
children
osa
malocclus
treat
rme
report
similar
result
obtain
one
year
treatment
rme
preschool
schoolag
non
obes
children
osa
dental
malocclus
signific
drop
clinic
symptom
well
apneahypopnea
index
studi
also
demonstr
start
treatment
earli
bone
still
extrem
plastic
growth
rate
maximum
increas
percentag
success
rme
treatment
twoyear
follow
end
rme
applic
perform
popul
children
confirm
stabl
decreas
apneahypopnea
index
increas
mean
overnight
oxygen
satur
persist
improv
clinic
symptom
final
recent
random
studi
show
preliminari
result
regard
effect
rme
appli
adenotonsillectomi
compar
effect
rme
appli
surgeri
children
osa
signific
differ
two
differ
approach
describ
conclus
orthodont
treatment
valid
treatment
osa
improv
clinic
symptom
respiratori
paramet
measur
psg
long
last
effect
widen
maxilla
correct
dental
malocclus
correct
relationship
maxillari
mandibular
arch
respect
anterior
cranial
base
main
craniofaci
chang
induc
rme
may
explain
efficaci
orthodont
therapi
orthodont
therapi
encourag
pediatr
osa
earli
approach
may
perman
modifi
nasal
breath
respir
therebi
prevent
obstruct
upper
airway
toward
turn
centuri
david
gozal
group
publish
seri
paper
rais
import
question
sampl
st
grade
pupil
whose
school
perform
lowest
decil
class
rank
found
sleepassoci
intermitt
hypoxia
andor
hypercapnia
school
perform
improv
whose
parent
opt
adenotonsillectomi
show
year
old
poor
school
perform
parentreport
snore
age
compar
among
good
school
perform
final
group
first
grader
snore
obstruct
sleep
apnea
ie
obstruct
apnea
index
perform
wors
measur
relat
attent
social
problem
visuospati
function
nonsnor
suggest
simpl
snore
may
benign
hitherto
wide
believ
background
set
perform
hannov
studi
sleep
apnea
childhood
hassac
communitybas
crosssect
studi
sever
aspect
sleepdisord
breath
sdb
primari
school
children
incorpor
twophas
sequenti
screen
procedur
particip
screen
symptom
sign
sdb
use
sdbquestionnair
home
puls
oximetri
hpo
outli
result
either
screen
method
subsequ
underw
abbrevi
home
polysomnographi
hpsg
final
diagnosi
obstruct
sleep
apnea
syndrom
osa
overal
particip
repres
underli
popul
thirdgrad
studi
region
found
cohort
habitu
snorer
popul
preval
osa
want
know
symptom
affect
behavior
academ
achiev
use
parent
questionnair
collect
teacher
rate
defin
poor
school
perform
grade
wors
last
school
report
form
requir
special
assist
classif
roughli
correspond
lowest
quintil
class
found
children
habitu
snore
compar
never
snore
time
odd
daytim
symptom
hyperact
difficulti
concentr
fall
asleep
watch
tv
school
peer
problem
time
odd
poor
school
perform
mathemat
scienc
spell
clear
doseeffect
gradient
ie
proport
children
poor
school
perform
increas
increas
frequenc
parentreport
snore
consid
high
preval
assum
causal
link
disturb
behavior
habitu
snore
appear
substanti
public
health
problem
primari
school
children
given
associ
want
know
mediat
ie
whether
mainli
detriment
effect
intermitt
hypoxemia
like
due
recurr
arous
contrari
hypothesi
increas
odd
poor
school
perform
daytim
symptom
associ
habitu
snore
stay
children
exhibit
intermitt
desatur
overnight
puls
oximetri
record
exclud
suggest
even
socal
benign
snore
ie
snore
without
hypoxemia
may
fact
benign
via
intermitt
desatur
could
relationship
poor
school
perform
mediat
via
frequent
arous
elicit
recurr
obstruct
apnea
address
question
took
advantag
fact
children
abnorm
questionnair
score
hassac
studi
also
underw
hpsg
thu
reanalyz
data
relationship
snore
daytim
symptom
poor
school
perform
exclud
children
mixedobstruct
apneahypopnea
index
maohi
risk
poor
school
perform
reduc
among
snorer
exclud
recurr
apnea
given
simpl
snore
strong
associ
daytim
symptom
revers
hassac
studi
could
collect
followup
data
snorer
control
among
snorer
stop
snore
score
emot
problem
hyperact
problem
peer
improv
school
perform
line
data
suggest
reduc
score
execut
function
iq
seen
children
prior
adenotonsillectomi
may
improv
follow
oper
similarli
avon
longitudin
studi
parent
children
alspac
even
whose
sdb
symptom
peak
age
month
abat
thereaft
still
almost
twice
odd
hyperact
higher
odd
behavior
problem
age
year
taken
togeth
grow
bodi
evid
frequent
snore
children
may
benign
previous
thought
may
instead
associ
impair
behavior
poor
academ
achiev
problem
may
even
persist
snore
ceas
statist
associ
confirm
causal
would
argu
earli
recognit
treatment
encourag
see
anoth
longitudin
studi
snore
daytim
symptom
proport
children
snore
age
year
breastf
less
month
breastf
month
longer
suggest
breastfeed
may
reduc
risk
snore
earli
childhood
addit
given
limit
avail
sleep
lab
urgent
need
better
easiertoperform
screen
method
identifi
may
need
treatment
snore
eg
poor
school
perform
predict
screen
test
also
intervent
nasal
steroid
montelukast
orthodont
treatment
may
deserv
studi
diagnosi
osa
use
home
respiratori
polygraphi
hrp
alonsoalvarez
et
al
prospect
assess
diagnost
reliabl
hrp
children
age
year
clinic
suspicion
osa
found
sensit
specif
conclud
hrp
emerg
potenti
use
reliabl
approach
diagnosi
moder
sever
osa
children
druginduc
sedat
endoscopi
dise
aim
reproduc
upper
airway
obstruct
sleep
gain
increas
popular
hope
guid
effici
surgeri
cure
osdb
children
metaanalysi
galluzi
et
al
conclud
dise
may
benefit
minor
children
osa
use
children
unremark
clinic
evalu
upon
persist
osa
obstruct
sleepdisord
breath
obes
pathogenesi
osa
obes
adolesc
literatur
pathogenesi
osa
adolesc
limit
schwab
et
al
prospect
compar
upper
airway
magnet
reson
imag
adolesc
age
year
result
indic
lymphoid
tissu
rather
soft
tissu
compon
tongu
later
pharyng
wall
parapharyng
fat
pad
primari
upper
airway
anatom
risk
factor
osa
pathogenesi
osa
clearli
multifactori
eg
decreas
upper
airway
reflex
osa
obes
adolesc
often
requir
addit
treatment
result
clinic
import
sinc
suggest
still
consid
firstlin
treatment
adolesc
osa
osdb
metabol
syndrom
systemat
assess
literatur
interact
sleep
osdb
obes
disrupt
metabol
homeostasi
children
adolesc
hakim
et
al
conclud
obes
osdb
appear
contribut
initi
progress
link
metabol
phenotyp
one
intrigu
mechan
postul
osdb
disrupt
sleep
well
factor
favor
obes
highfat
fructos
diet
disrupt
gut
microbiom
lead
increas
system
level
lipopolysaccharid
turn
promot
inflamm
metabol
dysfunct
treatment
sleepdisord
breath
children
watch
wait
chervin
et
al
follow
children
age
year
mildmoder
osa
seven
month
watch
wait
found
resolut
osa
children
independ
predictor
resolut
lower
ahi
normal
waist
circumfer
author
conclud
practic
baselin
low
ahi
normal
waist
circumfer
low
pediatr
sleep
questionnair
snore
score
may
help
identifi
opportun
avoid
myofunct
therapi
mt
camacho
et
al
perform
metaanalysi
use
mt
treatment
osa
adult
children
although
total
number
patient
especi
children
n
low
effect
highli
signific
overal
mt
decreas
ahi
pediatr
adult
patient
children
posit
effect
report
use
treatment
mild
osa
well
consolid
osa
cure
rapid
maxillari
expans
author
conclud
mt
could
adjunct
osa
treatment
patient
age
evolut
obstruct
sleepdisord
breath
children
evolut
preschool
children
osdb
walter
et
al
investig
longterm
evolut
osdb
preschoolag
children
normal
weight
half
preschool
osdb
treat
often
adenoidectomi
andor
tonsillectomi
overal
osdb
resolv
half
children
either
spontan
treatment
howev
still
osa
similarli
observ
schoolag
children
intriguingli
complet
resolut
osdb
three
year
posttreat
like
preschool
moderatesever
osa
compar
mild
osa
primari
snore
longterm
evolut
osa
spilsburi
et
al
report
result
remiss
incid
osa
particip
underw
psg
year
age
author
first
observ
osa
middl
childhood
usual
remit
adolesc
secondli
habitu
snore
obes
predict
osa
time
point
distinct
addit
risk
factor
osa
found
middl
childhood
vs
adolesc
henc
prematur
disadvantag
neighborhood
africanamerican
origin
also
predict
osa
middl
childhood
risk
factor
adolesc
includ
male
sex
previou
final
obes
habitu
snore
middl
childhood
predict
adolesc
osa
result
confirm
prevent
treatment
obes
appear
utmost
import
fight
pediatr
osa
evolut
osa
treatment
lee
et
al
perform
metaanalysi
psg
find
osa
obes
nonobes
children
overal
success
rate
postop
ahi
event
h
obes
vs
nonobes
postop
ahi
posit
correl
ahi
bodi
mass
index
surgeri
author
conclud
residu
osa
persist
children
especi
children
sever
osa
obes
